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ABSTRACT
Molecular Analyses o f Hematological Malignancies
Z. Buket YILMAZ
M.Sc. in Molecular Biology and Genetics 
Supervisor: Assoc. P rof Dr. Tayfim Oz9elik 
August 1998, 140 pages
Normal hematopoiesis is known to be disrupted in hematological malignancies. As 
research advances, many new treatment techniques are introduced, among which 
allogeneic transplantation is the most effective. In patients who undergo such 
treatment, different hematopoietic chimeric states may result which can be detected by 
indirect analyses using DNA polymorphisms. MRD (minimal residual disease) 
describes leukemia cells present at a level below that is detectable by conventional 
means. The detection o f MRD has gained special significance in transplantation 
patients. The detection o f fusion transcripts that are generated by chromosomal 
rearrangements in various hematological malignancies is the direct and the most 
powerful approach for the detection o f MRD. It not only has a prognostic significance 
but also has a diagnostic importance for patients who have not taken any treatment.
The aim o f this thesis is the development o f PCR-based tests for the diagnosis and 
monitoring o f patients with different hematological malignancies. Therefore the 
chimerism status o f 22 recipient-donor pairs have been evaluated by PCR 
amplification o f STR and VNTR polymorphisms followed by polyacrylamide gel 
electrophoresis and silver staining. In addition, 44 patients with acute and chronic 
leukemias have been analyzed for the detection o f fusion transcripts generated by t 
(9;22) (q34 ;q ll), t (8;21) (q22;q22), t (15;17) (q22;q21), inv 16 (pl3;q22), t (4;11) 
(q21;q23), and t (1;19) (q23;p23) chromosomal rearrangements with RT-PCR.
m
ÖZET
Hematolojik Kanserlerde Moleküler Analiz
Z. Buket YILMAZ
Yüksek Lisans Tezi, Moleküler Biyoloji ve Genetik Bölümü 
Tez Damşmam: Doç. Dr. Tayfun Özçelik 
Ağustos 1998, 140 sayfa
Hematolojik kanserlerde normal hematopoezin zarara uğradığı bilinmektedir. 
Araştırmalardaki gelişmelere paralel olarak aralannda allojenik kemik iliği 
transplantasyonunun en etkili olduğu, birçok tedavi tekniği uygulamaya girmiştir. Bu 
tür tedavi alan hastalarda, DNA polimorfizmlerinin kullamidığı dolaylı analiz 
yöntemleriyle tespit edilebilecek değişik kimerizm durumları görülmektedir. MRD 
(minimal residüel hastalık), standart analiz yöntemleriyle tespit edilebilecek seviyenin 
altındaki lösemi hücrelerinin varlığım ifade etmektedir. MRD analizi, transplantasyon 
hastalarında özel bir önem kazanmıştır. Değişik kan kanserlerinde kromozomlar arası 
parça değişimleriyle ortaya çıkan füzyon transkriptlerinin analizi, MRD tespitindeki 
doğrudan ve en etkili yöntemdir. Bu yöntem, prognostik özelliğinin yam sıra, herhangi 
bir tedavi almamış hastalar için diagnostik açıdan da önem taşımaktadır.
Bu tezin amacı, hematolojik kanser hastalannda diagnostik ve prognostik amaçlı 
olarak PCR (polimeraz zincir reaksiyonu) yöntemine dayalı testlerin geliştirilmesidir. 
Bu amaca yönelik olarak, STR ve VNTR polimorfizmlerinin amplifikasyonu, bunu 
takiben poliakrilamid jel elektroforezi ve gümüş boyama yöntemleriyle 22 ahcı-verici 
çiftindeki kimerizm durumu değerlendirildi. Buna ek olarak, RT-PCR yöntemiyle t 
(9;22) (q34 ;q ll), t (8;21) (q22;q22), t (15;17) (q22;q21), inv 16 (pl3;q22), t (4;11) 
(q21;q23) ve t (1;19) (q23;p23) kromözomlar arası parça değişimleri sonucu ortaya 
çıkan füzyon transkriptlerinin analizi için, 44 akut ve kronik lösemi hastası incelendi.
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I. INTRODUCTION
I. 1. HEMATOPOIETIC SYSTEM AND HEMATOLOGICAL
MALIGNANCIES
1.1 Hematopoiesis : Genesis and Differentiation of Blood Cells
Hematopoiesis is the formation of blood cells (Fauci et a i, 1998). The bone marrow, 
lymph nodes, and spleen are all involved in hematopoiesis. These organs and tissues 
have traditionally been divided into myeloid tissue including the bone marrow and the 
cells derived from it- erythrocytes, platelets, granulocytes, and monocytes, and 
lymphoid tissue consisting o f thymus, lymph nodes, and spleen (Cotran et al., 1989).
Maximow, in 1924, postulated that blood cells were derived from a single class of 
progenitors. In 1938, Downey added the concept o f hierarchies o f pluripotent cells. 
The demonstration that single cells were capable o f establishing nodules of 
hematopoietic growth in the spleen of irradiated mice and that such colonies displayed 
midtilineage or pluripotent differentiation (erythroid, myeloid, megakaryocytic) came 
in 1961 by Till and McCulloch. These landmark experiments established that a stem
1
cell existed for hematopoiesis. A stem cell is a cell with the ability o f self renewal and 
the production o f progeny destined to differentiate (Lee et al., 1993).
The common pluripotent hematopoietic stem cell gives rise to lymphoid stem cells and 
the trilineage myeloid stem cells respectively (Figure 1).
ui·· ' ‘ io
Figure 1; Differentiation of Hematopoietic Cells (Cotran a/., 1989)
The lymphoid stem cell is the origin o f precursors of T cells (pro-T cells) and B cells 
(pro-B cells). The former differentiates into mature T cells under the inductive 
influence o f the thymus and the latter to mature B cells under the influence of bursa- 
equivalent tissue. An important difference between lymphoid and myeloid 
differentiation is that, there are no distinctive, morphologically recognizable stages in 
lymphoid differentiation. From the multipotent myeloid stem cell, three types o f 
committed stem cells arise which differentiate along the erythroid / megakaryocytic, 
eosinophilic, and granulocyte / macrophage pathways (Cotran et al., 1989).
Pluznik and Sachs and Bradley and Metcalf reported that hematopoietic colonies 
could be grown in semisolid medium (Lee et al., 1993). Thus, the committed stem 
cells have been called the colony - forming units (CFU). As it is indicated in Fig. 1, 
granulocytes and macrophages have a common precursor, CFU-G / M, which gives 
rise to colonies having a mixture of neutrophils and macrophages. In the erythroid 
pathway, two distinct committed stem cells can be recognized. Based on the 
morphology o f the colonies, BFU-E (burst-forming unit-eiythroid) is the more 
primitive one. The later stage is CFU-E. From all these different committed stem cells, 
intermediate stages are derived, and finally the morphologically recognizable 
precursors o f  the differentiated cell lines are formed. These are, proerythroblasts, 
myeloblasts, megakaryoblasts, monoblasts, and eosinophiloblasts which in turn give 
rise to mature progeny . The mature blood elements have a finite life span and their 
numbers must be constantly replenished. Thus, self renewal is an important property
of stem cells. The pluripotent stem cells have the greatest capacity o f self renewal, but 
normally most o f them are not in cycle. Self renewal ability declines as commitment 
proceeds, but a greater fraction of the stem cells are found in cycle (Cotran et al., 
1989).
During the development o f systems for the growth o f hematopoietic colonies in vitro, 
it was understood that, in the absence o f either serum or conditioned medium, 
hematopoietic colonies did not grow. It was then demonstrated that glycoproteins 
termed colony-stimulating factors (CSF) were necessary for granulocyte-macrophage 
colony growth (Lee et al., 1993). Some hematopoietic growth factors and their 
characteristics are summarized in Table 1.
1.2 Description and Function of Bone Marrow
The bone marrow is a reservoir of stem cells which also provides a unique 
microenvironment for the proliferation and the differentiation of precursor cells. In 
addition, it regulates the release of fully differentiated cells into the circulation. Both 
structural (stromal) and humoral components of the bone marrow are involved in 
support of hematopoiesis (Cotran et al., 1989).
The marrow is a highly organized and complex organ. It is a gelatinous material 
interspersed within trabecular bone, which is supported by the cylindric medullary 
bone. A complex network o f vessels organized into repeating units supplies the 
marrow cavity. Venous sinusoids, which are surrounded by hematopoietic tissue in 
which blood cell formation takes place, is formed by the combination of small vessels 
that reenter the marrow cavity. The production o f the various marrow cells takes 
place by a ‘colonial’ proliferation o f islands o f erythroid or granulocytic cells, rather 
than by random distribution. Sinusoids are formed before myeloid hematopoiesis 
begins in the fetus. The venous sinusoids which eventually flow into a central vein, 
thus seem to be essential for hematopoiesis. The stromal elements of the marrow have 
been proposed as major factors in. the regulation o f hematopoiesis mainly through the 
mechanism o f various cytokines that they export (Lee et al., 1993).
Table 1 : Hematopoietic Growth Factors and Some of Their Characteristics
Factor* Cells Stimulated Production Sources
CSF-1
(M-CSF)
Monocytes Endothelial cells, 
monocytes, fibroblasts
GM-CSF All granulocytes, megakaryocytes, 
erythrocytes, stem cells, leukemic blasts
T cells, endothelial cells, 
fibroblasts
G-CSF Granulocytes, macrophages, endothelial 
cells, fibroblasts, leukemic blasts
Endothelial cells, 
placenta, monoc34es
IL-3 Granulocytes, erythroid cells, multipotential 
progenitors, leukemic blasts
T cells
IL-4 B, T cells T cells
E.-5 B cells, CFU-Eo T cells
IL-6 B, T cells, CFU-GEMM, CFU-GM, BFU-E, 
macrophages, neural cells, hepatocytes
Fibroblasts leukocytes, 
epithelial cells
IL-7 B cells Leukocytes
IL-8 T cells, neutrophils Leukocytes
E.-9 BFU-E, CFU-GEMM Lymphocytes
IL-11 B, T cells, CFU-GEMM, macrophages Macrophages
Erythropoietin CFU-E, BFU-E Kidney, liver
*GM, granulocyte-macrophage; IL, interleukin; GEMM, granulocytes, eiythroid cells, 
macrophages, megakaryocytes (Leei?/a/., 1993).
1.3 Hematological Malignancies
Hematological malignancies arise as a clonal proliferation o f one o f the hematopoietic 
progenitor cells. The clinical manifestations of a particular malignancy depend on the 
stage o f differentiation and lineage o f the affected cell. The specific nature of the 
initial mutation and o f subsequent mutations that may take place during clonal 
evolution is also critical. The abnormal clone o f cells must possess either a growth 
advantage or a block in apoptosis and / or differentiation over the normal cells. In 
lymphocyte proliferation, a causative mechanism has been shown to be a block in fas- 
mediated apoptosis. Clonal analysis o f mature blood cells indicates that many 
myeloproliferative and / or myelodysplastic disorders generally arise in the pluripotent 
stem cell (Fauci et al., 1998). The relationship between clonality and transformation 
into acute leukemia is summarized in Figure 2.
Figure 2 : Clonality and Transformation in Acute Leukemia
(Adapted from Lee et al., 1993)
1.3.1 Leukemias
The term leukemia was derived from the Greek word meaning ‘white blood’ and was 
first described by John Hughes Bennett and Rudolf Vichow in 1845 (Guinn B.A., and 
Padua R.A., 1997). The leukemias are a heterogeneous group o f neoplasms that arise 
from the malignant transformation of hematopoietic cells (Wilson et al., 1991). This 
group o f cancers arise in immature hematopoietic cells and leukemias are constantly 
characterized by the disturbance o f normal hematopoiesis and some degree of failure 
in production of normally functioning cells. The associated clinical features appear to
reflect the level and the lineage in the stem cell hierarchy at which malignant 
transformation has taken place. Leukemia represents approximately 5% of all cancers 
(Guinn B.A., and Padua R.A., 1997).
Leukemic cells proliferate primarily in the bone marrow and lymphoid tissues where 
they interfere with normal hematopoiesis and immunity. The accumulation of 
leukemic cells in the bone marrow is both due to excessive proliferation and to a 
defect in terminal maturation. These cells further enter the circulation and infiltrate 
into other tissues such as lymph nodes, liver, spleen, skin, viscera and the central 
nervous system (Wilson etal., 1991).
Environmental toxins (e.g. benzene or other industrial chemicals), cancer 
chemotherapy, radiation, and viruses such as HTLV-I (human T-cell lymphotropic 
virus type-I in adult T-cell leukemia / lymphoma) are among the well-established 
leukemogenic factors. Several hereditary factors have also been implicated as 
significant risk factors in leukemia, especially in childhood. Most o f them appear to be 
related to either some form of immune deficiency (agammaglobulinaemia, severe 
combined immunodeficiency, adenosinedeaminase deficiency), or a syndrome o f 
chromosomal instability (Down syndrome) (Wilson et al., 1991).
Disruption o f Hematopoiesis in Leukemia
A limited number o f hematopoietic stem cells sequentially enter into cell cycle. These 
then differentiate into multiple lineages in the peripheral blood and lymphoid organs. 
According to the traditional concepts o f hematopoietic development, progenitor cells 
differentiate into a single phenotype without the ability to switch lineage. In general, 
leukemic transformation involves a particular lineage. However, some adult acute 
leukemias are “biphenotypic” in nature with the expression o f both lymphoid and 
myeloid lineage cell surface antigens. In addition, in a subset of acute leukemias, 
lymphoid or myeloid lineage markers fail to be expressed and these are known as 
acute undifferentiated leukemias. Such leukemic cells may represent leukemic 
expansion o f the stem cell itself with no lineage markers (Sawyers et a l, 1991).
Classification o f Leukemias
The cell type involved and the state of maturity of the leukemic cells are the 
traditional bases on which leukemias are classified. Thus, acute leukemias are 
characterized by the presence o f veiy immature cells, blasts, and by a rapid fatal 
course in untreated patients. On the other hand, chronic leukemias are at least initially 
associated with well-differentiated, mature, leukocytes and with a relatively slow 
course. There are two major variants o f acute and chronic leukemias: lymphocytic and 
myelocytic (myelogenous). Therefore a simple classification yields four patterns o f
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leukemia: acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), 
acute myelocytic (myeloblastic) leukemia (AML), and chronic myelocytic leukemia 
(CML) (Cotran et al., 1989).
FAB and MIC Classifications
In 1976, a uniform classification system for acute leukemias and myelodysplastic 
syndromes was developed by an international group o f investigators. This system, 
known as the FAB (French-American-British) classification, is based on the 
morphologic appearance of bone marrow and blood leukemic blasts. This 
classification system has been adopted to allow comparison of treatment results and to 
take advantage of biologic differences between morphologic subtypes (Lee et al., 
1993).
A classification system based solely on morphological criteria proved to be 
inadequate. Therefore an additional system was introduced. Morphological, 
immunological and cytogenetic methods were integrated into this new classification 
by the M IC  (Morphological, Immunological and Cytogenetic) Cooperative Study 
Group, but not all acute myeloid leukemias could be categorized by this classification 
as well (Segeren C. M., and van’t Veer M. B., 1996).
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Nevertheless, immunophenotyping can be helpful in confirmation o f the diagnosis of 
AML and is necessary in differentiation o f AML-Mo and AML-M7 from ALL (Table 
2). However, it makes no contribution in distinguishing between AML and MDS. In 
this case, cytogenetic analysis will add important information as in MDS, numerical 
chromosomal abnormalities are more frequently observed while in de novo AML 
translocations are common. Immunophenotyping also is indispensable for the 
classification o f acute undifferentiated leukemia which is not described in FAB 
classification. In the FAB classification, there is a strict discrimination between AML 
and ALL. However, less than 5% of leukemias are biphenotypic and in this case, this 
classification is lacking and immunophenotyping is essential for the recognition of 
these types o f leukemia (Segeren C. M., and van’t Veer M. B., 1996).
1.3.1.1 Acute Myeloblastic Leukemia (AML)
The term ‘acute non-lymphocytic leukemia (ANLL) is also used for this group of 
leukemias. Acute myeloblastic leukemias primarily affect adults between ages o f 15 
and 39 years and constitute only 20% of childhood leukemias (Cotran et al., 1989). 
The incidence o f AML is approximately 2.3 per 100,000 people per year and it 
increases with age (Fauci et al., 1998). The extraordinary heterogeneity o f AML 
reflects the complexities of myeloid cell differentiation. This group o f leukemias are o f 
diverse origin. Some arise by transformation o f multipotent (trilineage) myeloid stem
12
cells while in others the common granulocyte-monocyte precursor is involved (Fig 1).
In the widely used FAB classification, AML is divided into eight categories (see Table 
2) taking into account both the degree o f maturation (M l to M3) and the predominant 
line o f differentiation of the leukemic stem cells (M4 to M7) (Cotran et al., 1989).
Table 2 : FAB Classification of Acute Myeloblastic (Myelocytic) Leukemias
Subtype % of Cases *
Mo Acute myeloblastic leukemia 
with no maturation
2-3 %
Ml Acute myeloblastic leukemia 
with minimal maturation
20%
M2 Acute myeloblastic leukemia 
with maturation
25-30 %
M3 Acute promyelocytic leukemia 8-15 %
M4 Acute myelomonocytic leukemia 20-25 %
M5a Acute monoblastic leukemia 
without differentiation 20-25 %
M5b Acute monoblastic leukemia 
with differentiation
M6 Acute erythroleukemia 5 %
M7 Acute megakaryocytic leukemia 1-2 %
* Percentages are approximations (Fauci et al., 1998).
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Chromosomal abnormalities have been observed in approximately 90 % o f all AML 
cases. Many o f the nonrandom chromosomal abnormalities have prognostic 
implications which do not depend on other clinical prognostic factors. These are 
summarized in Table 3.
Table 3 : Chrom osom al Abnormalities in A M L and Their Significance
Chrom osom e
A bnorm ality
FAB
Subgroup
Frequency Com m ent
t (9;22) Ph chr. M l 3 % Poor to intermediate prognosis
t (8;21) M2 20% More often in younger males, 
good prognosis
t(15;17) M3 70-100% Unique to M3, intermediate 
prognosis
inv 16 or del 16q M4 ~ 25 % Good prognosis
del l lq o r t ( l l ;V * ) M5, some M4 30% Intermediate prognosis
+8 M l, M2, M4, Variable Common abnormality in
M 5,M 6
-7 or del (7q) 
-5 or del (5q)
hemotopoietic neoplasms, no 
prognostic association
Most frequently seen in patients 
older than 60 years in secondary 
leukemias associated with 
exposure to environmental or 
occupational carcinogens
V* = Variable chromosomes (Cotran etal., 1989)
14
Acute lymphoblastic leukemia is primarily a disease o f children and young adults. 
ALL can be subdivided by morphologic and immunologic criteria. Morphologic 
subtypes designated as L I, L2, and L3 have been defined in the FAB classification o f 
acute leukemias. An alternative immunologic classification is also commonly used and 
is based on the origin o f the leukemic lymphoblasts and their stage of differentiation. 
It is defined by cell surface markers and antigen receptor gene rearrangements (Cotran 
etal., 1989).
1.3.1.2 Acute Lymphoblastic Leukemia (ALL)
Table 4 : Classification of Acute Lymphoblastic Leukemia (ALL)
Immunologic % of Cases FAB Subtype 
Subtype
Pre-B ALL
T cell ALL
B cell ALL
75
20
LI, L2
L L L 2
L3
Cytogenetic
Abnormalities
t (9 ;2 2 ) ,t(4 ; l l ) ,
t ( i ; i9 )
14ql 1 or 7q34
t(8 ;14 ),t(8 ;22 ),
t(2;8)
(Adapted from Fauci et al., 1998).
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Chronic myelogenous leukemia (CML), is a clonal myeloproliferative disorder which 
results from the neoplastic transformation o f the primitive hemopoietic stem cell. The 
disease is monoclonal in origin, affecting myeloid, monocytic, erythroid, 
megakaryocytic, B-cell, and sometimes T-cell lineages. CML is historically important 
in two aspects. First, it was the first disease in which a specific chromosomal 
abnormality t (9;22) (q34;qll) or Philadelphia chromosome was linked to the 
pathogenesis o f the disease. Second is at the therapeutic level, CML is one o f the first 
neoplastic diseases in which the use of a biologic agent, interferon, could suppress the 
neoplastic clone and prolong survival. Bone marrow transplantation (BMT) studies in 
CML have also given impressive results (Cortes et a i, 1996).
CML accounts for 7-15 % of all leukemias in adults with an incidence of 1-1.5 cases 
per 100,000 population. The median age at presentation is 53 years, but the disease 
can be seen in all age groups. The etiology of the disease is not clear. There is little 
evidence for genetic factors linked to CML. It has been suggested that there may be 
some correlation with HLA antigens CW3 and CW4. Therapeutic radiation has also 
been associated with increased risk o f CML (Cortes et al., 1996).
CML has a bi- or triphasic course. There is an initial chronic phase eventually leading 
to a blastic phase, which is sometimes preceded by an intermediate or accelerated
1.3.1.3 Chronic Myelogenous Leukemia (CML)
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phase (Cortes et al., 1996). Blast crisis is characterized by increased cellular 
proliferation, maturation arrest, and karyotypic clonal evolution (Wada ei al., 1994).
A classification of CML and .its variants is shown in Table 5.
Table 5 : A Classification of CML
Clinical Variants
Typical CML (Ph chromosome present) 
Atypical CML (Ph chromosome absent) 
CML in infants
(Leeetuf/., 1993)
1.3.2 Lymphomas
Morphologic Variants
Chronic eosinophilic leukemia 
Chronic basophilic leukemia 
Chronic monocytic leukemia 
Chronic neutrophilic leukemia
The malignant lymphomas, in contrast to leukemias, are neoplastic transformations of 
cells that reside predominantly in lymphoid tissues. The two major variants of 
malignant lymphoma are non-Hodgkin’s lymphoma and Hodgkin’s disease. For the 
classification o f the lymphoid malignancies, the Revised European-American 
Classification of Lymphoid Neoplasms (R.E.A.L.) has been created. (Fauci et al..
1998).
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Non-Hodgkin’s lymphomas occur in the cases o f drug-induced immunosuppression 
and acquired or congenital immunodeficiency. Such lymphomas develop in 30 % of 
HIV-1 infected individuals and 40-50 % are EBV (Epstein-Barr Virus) associated. At 
the molecular level, chromosomal translocations have been demonstrated to be 
involved in induction of non-Hodgkin’s lymphoma. Genes that normally regulate 
heavy and light chain immunoglobulin synthesis are juxtaposed to genes that regulate 
normal cellular activation and proliferation. The postulation is that, these transforming 
oncogenes come under the control of those regulatory elements that normally control 
B cell proliferation and differentiation (Fauci etal., 1998).
Hodgkin’s disease usually presents as a localized disease with a subsequent spread to 
contiguous lymphoid structures and a final dissemination to non-lymphoid tissues. 
There is strong evidence for a role of EBV in the pathogenesis o f the disease. In 
contrast to non-Hodgkin’s lymphomas, where chromosomal deletions and 
translocations are common, cytogenetic studies have shown that such abnormalities 
are uncommon in Hodgkin’s disease. Diagnosis depends on identification of large 
multinucleated reticulum cells (Reed-Stemberg cells) in lymph node tissue or other 
sites (Fauci et al., 1998).
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Myelodysplastic syndromes, also referred to as preleukemic disorders, are a group o f 
clonal acquired blood disorders affecting the hematopoietic stem cells and that often 
progress into acute leukemia. MDS results from neoplastic transformation of the 
pluripotent stem cell with involvement of myeloid, and less commonly, o f lymphoid 
lineages. The myeloid cells in MDS have their ability to proliferate and differentiate, 
but they undergo an abortive maturation which results in an inadequate major blood 
cell production (Fauci et al., 1998).
Among the common chromosomal abnormalities are, monosomy 7, 5q-, and trisomy 8 
together with a variety of translocations. Molecular studies have demonstrated an 
increased incidence of mutations involving the ras, cFms [monocyte colony- 
stimulating factor (M-CSF) receptor] ,p53 and RB genes (Fauci etal., 1998).
According to the FAB classification, there are five well-defined subtypes: refractory 
anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia 
with excess blasts (RAEB), refractory anemia with excess blasts in transformation 
(RAEB-t), and chronic myelomonocytic leukemia (CMML) (Fauci et al., 1998).
The information on the frequency and the leukemic transformation of these subtypes 
are summarized in Table 6. (See also Fig. 2).
1.3.3 Myelodysplastic Syndromes (MDS)
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Table 6 : FAB Classification and Leukemic Transformation in MBS
FAB Type % of Cases % Leukemic 
Transformation (Range)
RA 28 11 (0-20)
RARS 24 5 (0-15)
RAEB 23 20 (3-55)
CMML 16 23 (11-50)
RAEB-t 9 48 (11-75)
(Adapted from Fauci et al., 1998)
1.4 Chromosomal Rearrangements in Hematological Malignancies
The first consistent chromosome aberration observed in human neoplasia was the 
Philadelphia chromosome in CML in 1960. The proof that this is a consequence of a 
translocation came in 1973 by the improved chromosome banding techniques. 
Translocations have one of two effects. They may lead to the deregulation 
(overexpression) o f oncogenes by their juxtaposition to enhancer or promoter 
sequences that are active in the cell type from which the tumor arises, particularly the 
Ig and TCR enhancers. The alternative molecular consequence of translocations is
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gene fusion, which results in a chimeric oncoprotein, the contribution to whose 
transforming ability is from both partners (Solomon et a l, 1991).
The frequently seen chromosomal rearrangements, which have also been studied in 
the scope o f this thesis, involve five translocations and one inversion. Besides their 
frequent involvement in leukemias, the availability of samples for analysis was also 
taken into account. The rearrangements analyzed, their fusion gene products, disease 
association, affected age groups, and frequency in different leukemias is given in 
Table 7.
Table 7: Chromosomal Rearrangements Analyzed in the Scope of This Study
Rearrangement / Age
Translocation Fusion Gene Disease Group Frequency
CML; ...... 90% (CML);5% (P),
t (9;22) (q34; q ll) B C R /A B L AML (Ml) A /P 20% (A); 3% (Ml)
t (8;21) (q22; q22) E T O /A M L I AML (M2); APL A /P 40% (P), 6% (A); 95%
t (15;17) (q22; q21) M Y L /R A R - a AML (M3) A /P 70-100%
t (4;11) (q21; q23) ALL-1 /A F - 4 ALL (lymhoblastic) A /P 100%
t (1;19) (q23; p23) E2A /P B X -1 ALL (pre-B cell) P 20-25%
inv 16 (pl3; q22) C B F B /M Y H ll AML (M4Eo) A ~ 25%
A /P; Adult / Pediatric
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The Ph chromosome is the result o f a reciprocal translocation between the long arms 
of chromosomes 9 and 22. In 1984, Grofifen et al. located the breakpoints on 
chromosome 22 band q l 1 to a region of 5.8 kb, the breakpoint cluster region or bcr. 
Subsequent studies revealed that the bcr is part o f a large gene called the BCR gene. 
The bcr contains four exons (bl-b4), and chromosomal breaks occur in two introns 
between exons b2, b3, and b4. Breakpoints on chromosome 9 are scattered over a 
distance o f at least 100 kb, but are all located at the 5’ end of the tyrosine kinase 
domain of the c-abl oncogene (Hermans et al. 1987).
The normal BCR gene occupies a region o f about 135 kb on chromosome 22. It is 
expressed as mJRNAs of 4.5 and 6.7 kb, which encodes for the same cytoplasmic 160- 
kD protein, and contains 23 exons. The Bcr protein contains a unique serine / 
threonine kinase activity and at least two SH2 binding sites encoded in its first exon 
and a C-terminal domain that functions as a GTPase activating protein 
(http://www.ncbi.nlm.gov/htbin-post/Omim/dispmim7151410). BCR first exon 
sequences specifically activate the tyrosine kinase and transforming potential of BCR- 
ABL through interaction of SH2 domain o f ABL (Pendergast et al. 1991). The wild 
type Bcr has structural features that suggest a role in signal transduction. In addition 
to the novel serine /  threonine kinase domain, it has an oligomerization domain, a Rho 
guanine-nucleotide exchange factor (Rho-GEF) homology domain, and a calcium-
1.4.11 (9;22) (q34; q l l)
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dependent lipid binding site. Bcr knockout mice show defects in neutrophil superoxide 
bursts, suggesting a role for Bcr in the anti-microbial function o f myeloid cells 
(Raitano e ta l,  1997).
The ABL (Abelson strain o f murine leukemia virus) gene is about 225 kb in size and is 
expressed as either a 6- or 7-kb mRNA transcript, with alternatively spliced first 
exons, exons la  and lb respectively. The 145 kD protein is classified as a nonreceptor 
tyrosine kinase (http://www.ncbi.nlm.gov/htbin-post/Omim/dispmim7189980). It 
contains src homology domains SHI, SH2, and SH3. Its carboxy-terminal has a 
number o f important domains such as nuclear localization signals, a DNA binding 
domain, a p53 binding site, and an actin binding domain. Abl is expressed in all tissues 
and is localized in both nucleus and cytoplasm. Mice with targeted disruptions in the 
c-Abl gene have high neonatal mortality rates and increased susceptibility to infections 
suggesting a role in B-cell development, but its precise role is unclear (Raitano et al., 
1997).
As a result o f the translocation, the ABL gene is transferred from its normal position 
on chromosome 9 band q34 to the Ph chromosome. This creates a head-to-tail BCR- 
ABL juxtaposition on the Ph chromosome. The fusion gene is transcribed into an 8.5 
kb chimeric mRNA, lacking the first exon of ABL. The hybrid RNA is translated into 
a hybrid protein product o f 210 IcD (p210®^^‘'^^) and exhibits an in vitro tyrosine 
kinase activity . The Ph chromosome is also found in ALL (Ph+ ALL). Although ABL
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is translocated and a new fusion protein p i i s  formed, no breakpoints are
V
observed in the bcr (Ph+ bcr- ALL). Breakpoints in chromosome 22 occur within the 
same gene but more 5’ of the bcr. This fusion gene is transcribed into a 7 kb mRNA, 
encoding a novel fusion protein (Figure 3) (Hermans et al. 1987).
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BCR-ABL transforms hematopoietic cells in vitro and its expression in growth-factor 
dependent cell lines allows cytokine independent growth. Lethally irradiated mice 
reconstituted with BCR-ABL expressing BM cells develop different hematological 
malignancies including a CML-like syndrome (Raitano et a l, 1997).
1.4.2 t (8;21) (q22;q22)
The 8;21 translocation is one of the most common chromosomal translocations in 
AML. The chromosomal breakpoints involve Xh^AMLl gene on chromosome 21 and 
ETO gene on chromosome 8. Translocation results in the consistent fusion of these 
genes on the der (8) chromosome, resulting in the production of a novel chimeric 
gene and message (Figure 4) (Downing et al., 1993).
AMLl gene , on chromosome 21 q22, consists of nine exons and spans more than 150 
kb o f genomic DNA. It is highly homologous to the Drosophila segmentation gene 
nmt and the mouse transcription factor pebp2 (polyoma enhancer binding protein) a  
subunit gene. The region of homology, called the Runt domain, is responsible for 
DNA binding and protein-protein interaction (Miyoshi et al., 1995). To investigate 
the normal biologic function o f AMLl in vivo, Okuda et al. generated mice carrying a 
disrupted AMLl allele using gene targeting in embryonic stem (ES) cells. Mice 
lacking amll died during midembryonic development, secondary to the complete 
absence o f fetal-liver derived hematopoiesis. Besides, homozygous ¿Z7w//-deficient
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cells failed to contribute to hematopoiesis in chimeric animals indicating that, amll 
regulated target genes are essential for definitive hematopoiesis o f all lineages (Okuda 
e ta l ,  1996).
ETO ,also called MTG8 (myeloid translocation gene on 8), contains two DNA- 
binding zinc finger motifs and several regions that are proline- and serine-rich. It is 
thought to be a transcription factor due to the presence o f such motifs in other 
transcription factors (Nucifora G., and Rowley J. D., 1994). The relatively high levels 
o f ETO in developing brain suggests that it could be involved in the regulation of 
some aspect o f neuronal proliferation and differentiation (Erickson et al., 1994). In a 
recent study by Wang et al., ETO has been shown to have transforming properties. 
Ectopic ETO expression in NIH / 3T3 cells led to foci of transformation and colony 
growth in soft agar. £TO-expressing cells induced tumors following injection into 
irradiated nude mice suggesting an important role in the leukemogenic transforming 
potential of xheAMLl-ETO fusion protein (Wang et a i, 1997).
The fusion gene that results from the t (8;21) translocation contains the 5’ region o f 
AML I including the Runt domain fused to almost all o f ETO (Nucifora G., and 
Rowley J. D., 1994). Both Amll-Eto and the Amll proteins recognize the same 
consensus DNA-binding motif, which is found in promoters of several genes involved 
in hematopoiesis. BCL-2 is another gene in which this sequence specific binding o f
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both AM Ll and the fusion protein takes place. The elevated levels o f BCL-2 in cells 
expressing AMLl-ETO may prolong their life span and contribute to the development 
o f t(8;21) leukemia (Klampfer et al., 1996). In a recent study, mice that mimic human 
t(8;21) were generated. Mice heterozygous for AMLl-ETO allele die in midgestation 
from hemorrhaging in CNS and exhibit severe block in fetal liver hematopoiesis which 
is very similar to the phenotype obtained by homozygous disruption of the AMLl 
gene. This indicates that AMLl-ETO blocks normal AMLl function (Yergeau et al., 
1997).
1.4.3 t(15;17) (q22;q21)
A consistent translocation t(15;17) is present in the blasts o f the majority of the APL 
patients. The two genes involved are (also called PML) on chromosome 15, and 
RAR-a on chromosome 17. Chimeric RAR-a / MYL (on the 17q- derivative) and 
h'lYL / RAR-a (on the 15q+ derivative chromosome) are generated as a consequence 
of the reciprocal translocation (Figure 5) (Biondi etal., 1992).
Retinoic acid receptors (RARs) are nuclear hormone receptors that act as retinoic 
acid (RA)-inducible transcriptional activators in their heterodimeric form. RA controls 
fundamental developmental processes, induces terminal differentiation of myeloid 
hemotopoietic progenitors, and has tumor and cell growth suppressive activities. The 
chimeric PML-RAR-a protein contains most of the PML sequences fused to a large
2 8
part oiRAR-a, including its DNA and hormone binding domains (Wang et al., 1998).
PML is an interferon (IFN)-inducibIe gene that encodes a ring-finger protein which is 
typically concentrated within discrete speckled nuclear structures called PML nuclear 
bodies or PML oncogenic domains. Ablation o f murine Pml protein by homologous 
recombination revealed that PML regulates hemopoietic differentiation and controls 
cell growth and tumorigenesis. PML function is essential for the tumor growth 
suppressive activity of RA and for its ability to induce terminal myeloid differentiation 
o f progenitor cells. Thus PML is a critical component o f the RA pathway and 
disruption o f its activity by the translocation may be important in APL pathogenesis 
(Wang e /a /., 1998).
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1.4.4 inv 16 (pl3;q22)
The involvement o f chromosome 16 in leukemia was first reported in 1982 by Arthur 
and Bloomfield. In 1983, Le Beau et al demonstrated chromosome 16 inversion with 
AML-M4. In the following years, t(16;16) was identified, the breakpoints o f which 
seemed to be the same as in the inversion (Figures 6 and 7). Molecular studies 
showed that a fusion gene is generated by inv 16 between the CBFB gene on q arm 
and the M YH ll gene on p arm (Liu et al., 1995).
Figure 6: inv 16 (pl3;q22) Rearrangement
(Adapted from Claxton et al., 1994)
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CBFB gene encodes a subunit o f the transcription factor complex CBF, also known as 
PEBP2. PEBP2 was originally identified as a protein in N M  3T3 cells that binds to 
mouse polyoma virus enhancer. CBF was identified as a protein predominantly 
expressed in T cells that bind to a conserved “core” site in murine leukemia virus 
enhancers. Both PEBP2 and CBF recognize the same core site. The cloning and 
purification identified them as the same protein. CBF consists of two subunits: the a  
subunit, which binds the DNA target, and the |5 subunit, which does not bind DNA 
directly. At least three a  subunits have been identified one o f which is encoded by 
AMLl gene that is disrupted by t(8;21) and t(3;21) (Liu et al., 1995).
Figure 7: t (16; 16) (pl3;q22) Rearrangement
(Adapted fi-om Claxton e ta l,  1994)
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The smooth muscle myosin heavy chain (SMMHC) gene M YH ll is a member o f the 
myosin II family. A typical myosin II protein has an ATPase head, responsible for 
actin binding and mechanical movement, a hinge region, and a long tail with tandem 
copies o f a coiled-coil domain that facilitates the filament assembly. The breakpoints 
identified are within the tail region, fusing the C-terminal portion of the tail to CBFB 
(Liu et al., 1995).
1.4.5 t(4;ll)(q21;q23)
The t (4;11) (q21;q23) cytogenetic abnormality is associated with a subset of ALL. 
The two genes involved are AF-4 {FEL) and ALL-1 {MLL, mixed lineage leukemia or 
myeloid-lymphoid leukemia, HRX, homolog o f trithorax, Hrtx 7, human trithorax-like 
gene 1) on chromosomes 4 and 11 respectively. As a consequence o f the 
translocation, these genes are fused and transcribed as a chimeric ALL-1 / AF-4 
mRNA (Figure 8) (Cimino et al., 1996).
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The ALL-1 gene is found rearranged in approximately 10 % of ALL and in over 5 % 
o f AML. The gene undergoes fusion with different partners on a variety o f 
chromosomes such as chromosomes 1, 4, 6, 9 ,10, or 19. The gene, which spans a 
region on chromosome band llq23  approximately 90 kb in length, consists of 36 
exons (Rasio et al., 1996). ALL-1 gene belongs to the trithorax gene family of which 
the Drosophila trithorax (trx) gene is known to regulate homeotic genes through 
alternative splicing. Nam et al. demonstrated that, different cell t3q)es transcribe ALL- 
1 mRNA species lacking exons that generally encode putative regulatory domains 
such as AT hooks (exon3), repression domain (exon 6), zinc finger motifs (exon 8),
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and activation domain (exon 18). This suggests that posttranscriptional regulation by 
alternative splicing may play an important role in ALL-1 gene expression (Nam et al., 
1996). Immunoc5h;ochemical analysis showed that the protein localizes to nuclear 
structures in cells with and without llq23  translocations. It is widely expressed in 
most cell types including hematopoietic cells (Butler e ta l,  1997).
AF-4 (ALL-1 fused gene from chromosome 4), is a serine and proline rich putative 
transcription factor with a glutamine rich C-terminus. It is expressed normally in both 
B- and T-lymphoid cell lines . The ALL-1 / AF-4 fusion protein contains a large C- 
terminal portion o f AF-4 fused to the N-terminal portion o f ALL-1 containing its AT 
hook DNA binding motifs (Morrissey et a l, 1993).
1.4.6 t ( l ;  19) (q23;p23)
The prognostically important 1;19 chromosomal translocation can alter the E2A gene 
on chromosome 19pl3 in childhood B-cell precursor ALL, The breakpoint on 
chromosome lq23 interrupts a homeobox gene known as PBXl. As a result, chimeric 
transcripts are formed that retain the activator domain o f the E2A gene but substitute 
a homeobox domain o f the Pbxl protein for the helix-loop-helix DNA binding and 
dimerization domain ofE2A (Figure 9) (Privitera e ta l,  1992).
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E2A gene encodes transcription factors of the helix-loop-helix (HLH) family that are 
implicated in cell-specific gene expression as part of dimeric complexes that interact 
with E box enhancer elements. Its expression is detected in a wide range of celt lines. 
E2A gene gives rise to two proteins, E12 and E47, by differential splicing of E l 2- and 
E47- specific basic HLH encoding exons. Both have been implicated in the regulation 
o f Ig gene expression (Aronheim et al., 1993).
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I. 2. MOLECULAR DIAGNOSIS OF HEMATOLOGICAL MALIGNANCIES
2.1 Cytogenetics
Cytogenetics is the study o f the genetic material, genome or chromosomes, of a cell 
by cytological means. In molecular cytogenetics, the advantage of the specificity and 
base pairing qualities o f DNA is used to look at specific regions o f the genome to 
which it hybridizes. In hematological malignancies, cytogenetic analysis may be used 
for: (a) detection o f malignant proliferations, (b) classification of hematological 
neoplasms, (c) characterization of the degree o f neoplastic progression, (d) testing for 
remission (disappearance of signs o f cancer), and (e) establishment of the time of 
relapse (Kurzrock et al., 1995).
The application of banding techniques; especially Q (quinacrine fluorescence) and G 
(Giemsa) bandings are used for detailed characterization o f structural rearrangements 
within chromosomes (Lee etal., 1993).
Molecular cytogenetics provides a powerful link between molecular genetic analysis 
and chromosome morphology by allowing to pinpoint structurally aberrant 
chromosome regions on the molecular level (Lichter et al., 1996).
Fluorescence In Situ Hybridization (FISH)
In situ hybridization is the term used to describe a procedure in which labelled DNA 
is hybridized to cell or tissue preparations on slides. In molecular cytogenetics, this 
procedure is used to identify chromosomes or chromosome regions containing the 
probe sequences (Kurzrock et al., 1995).
The advantages o f this technique may be summarized as follows;
a. it allows the study o f chromosome changes by scoring large numbers o f non­
dividing cells in a relatively short time,
b. it enables better definition of the nature o f complex structural changes in 
metaphase cells,
c. it permits estimation o f the size of abnormal clones in interphase cells, and
d. it may help in determination of the lineage o f cells carrying a chromosome 
abnormality (Cuneo et al., 1997).
Besides FISH, there are other molecular cytogenetics methods such as comparative 
genomic hybridazation (CGH), which may prove to be very useful for diagnostic 
purposes in the coming years.
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2.2 Im m unological M ethods
In addition to C5dogenetic analysis, a variety o f immunologic techniques have been 
developed for more specific and accurate diagnosis. Immunofluorescence and 
immunoenzymatic techniques allow localization o f cell or tissue antigens on the 
surface, in the cytoplasm, or in the nucleus. In the direct immunofluorescence 
techniques, the antigen is identified by a fluorochrome-labelled specific antibody. The 
more sensitive indirect method utilizes an unlabelled specific primary antibody and 
allows it to react with the tissue antigen. A fluorochrome conjugated second antibody 
(anti-immunoglobulin) that binds to the primary antibody is then applied. 
Immunofluorescence techniques are used mostly to study cells in suspension by means 
of fluorescence microscopy or automated flow cj^ometers. There are also 
immunoenzymatic tests which utilize immunoperoxidase technique, the avidin-biotin 
complex system, and the immunoalkaline phosphatase technique (Lee etal., 1993).
2.3 Fusion Transcript Detection
Recurring chromosomal abnormalities are closely associated with particular 
phenotypes. This is especially the case for structural chromosomal changes seen in 
leukemias and lymphomas, which have diagnostic and prognostic implications. 
Molecular analysis of these changes not only yields important insights into disease 
pathogenesis but also provides more precise definition o f disease subsets which is
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critical in the management o f patients with these rearrangements (Claxlon et al., 
1994).
The advent o f polymerase chain reaction (PCR) technology has greatly facilitated the 
analysis o f small nucleic acid samples. In cases where there is sufBcient molecular 
information, reverse-transcriptase polymerase chain reaction (RT-PCR) is particularly 
useful. In this approach, the isolated RNA is converted to single-stranded cDNA 
(complementary DNA), which can then be used for enzymatic amplification of 
sequences between specific primers. The primers are designed such that amplification 
will be achieved only if the chromosomal rearrangement under question has taken 
place. Diagnostic PCR products are then easily detected by hybridization and / or 
electrophoresis techniques. Several advantages o f RT-PCR over other molecular 
methods can be listed as follows;
a. It is rapid and sensitive, fusion transcipts are amplifiable from cDNA synthesized 
from as little as 20 pg of total cellular RNA which is equivalent to the 2-5 cell 
level. Standard Southern gel analysis on the other hand, requires about 5% o f cells 
to be leukemic for the detection of deletions and / or translocations in genomic 
DNA.
b. PCR amplification o f coding sequences in genomic DNA requires knowledge of 
the exon-intron structure o f the gene, because interruptions of the coding 
sequences with large introns can make amplification diflBcult or impossible 
(Kawasaki a/., 1988).
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The accumulation o f leukemic blasts in bone marrow suppresses normal 
hematopoietic stem cells. Therapeutically the aim is to decrease population o f 
leukemic clone enough to allow the recovery o f normal stem cells (Cotran et al., 
1989).
In order to ‘cure’ a malignancy, all o f the cancer cells must be destroyed. Hormones, 
cytokines (interferons, interleukins, tumor necrosis factor), monoclonal antibodies 
coupled to tumoricidal agents, cells (lymphokine activated killer (LAK) cells, tumor 
infiltrating lymphocytes (TIL)), and chemotherapeutic drugs are among biologic and 
chemical agents which are used in cancer treatment (Wilson e ta /., 1991).
I. 3. TREATMENT OF HEMATOLOGICAL MALIGNANCIES
3.1 Chemotherapy and Biologic Agents
In order to achieve a cure with chemotherapeutic drugs, (1) the cancer cells must be 
sensitive to the agent; (2) the drug must reach the malignant cell; (3) if the drug is 
effective only in a phase of the cell cycle, it must be given frequent enough that all the 
cancer cells enter this phase o f the cycle in the presence o f the drug; and (4) the 
malignant cells must be destroyed before drug resistance emerges (Wilson et al., 
1991).
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Antineoplastic drugs exert their cytotoxic effects by interfering with different cellular 
mechanisms involved in cell growth. These include alkylating agents, antineoplastic 
antibiotics, plant alkaloids, and antimetabolites. Alkylating agents have their c)^otoxic 
effects through covalent binding of the alkyl groups to cellular DNA or other 
molecules. Examples are cyclophosphamide, the chlorethylnitrosoureas, and 
melphalan. Antineoplastic antibiotics, which are isolated from microbial fermentation 
extracts, are responsible for the improved treatment o f leukemias and lymphomas. 
They include bleomycin, doxorubicin, mitomycin, and mitoxantrone. Plant alkaloids, 
are also effective antineoplastic drugs derived from natural sources; examples are 
vincristine, vinblastine, etoposide and teniposide. Finally antimetabolites act by 
inhibiting crucial metabolic enzymes. 5-fluorouracil, methotraxate, and cytarabine are 
mostly effective on rapidly dividing cells (Wilson et al., 1991).
There are different biologic approaches to the treatment of cancer. These agents act 
through one o f the following mechanisms : (1) augmenting the defenses of the host, 
(2) direct tumoricidal effect, and (3) modification of the behaviour of the tumor. 
Cytokines and hematopoietic growth factors are frequently used biological agents 
(Wilson e /a /., 1991).
Granulocyte (G) or granulocyte-macrophage (GM) colony stimulating factors (CSF), 
interferon- a  (IFN-a), and interleukin 2 (IL-2) are among the widely used therapeutic 
agents. AML blasts have surface receptors for CSFs and may proliferate in response 
to CSFs. By this way, leukemic cells are sensitized by CSFs, made more susceptible to
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chemotherapy which enables to increase the dose intensity o f chemotherapeutic 
agents. CSFs have also been used to mobilize peripheral blood stem cells for 
autologous and allogeneic transplantation (Ezaki K., 1996).
Interferons originate from natural sources and are products of recombinant 
technology. There are three major classes of interferons: interferons alpha, beta, and 
gamma. Interferons alpha, which have antiviral, anticancer, and immunomodulatoiy 
activities, are secreted and synthesized by leucocytes and lymphoblasts. IFN-a 
therapy is used in the management of patients with hematological diseases, 
malignancies, lymphomas, solid malignant tumors and viral infections. For CML, it is 
considered as a first-line therapy, option in patients who cannot receive or relapse 
following allogeneic bone marrow transplantation (Bajcetic et al., 1998).
Vitamin A and its natural and synthetic derivatives, the retinoids are required for many 
essential life processes, including vision, reproduction, metabolism, differentiation, 
hematopoiesis, and bone development. There is also evidence that retinoids have a 
potent antiproliferative effect, and may be effective in the treatment of different 
human diseases including cancer. Apart from vision, retinoids exert these diverse 
effects by regulating gene expression at specific target sites within cells. The three 
retinoids of known biological importance are retinol, retinal, and retinoic acid (Sacchi 
etal., 1997).
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Studies over the last two decades demonstrated the capacity o f some substances to 
induce in vitro differentiation of human leukemia cell lines. In 1988, a Chinese group 
showed that by using all-trans retinoic acid (ATRA) alone, complete remission 
through differentiation of the leukemic clone was obtained in 94% of acute 
promyelocytic leukemia (APL) patients. One of the most important features of APL is 
the t(15;17) (q22;q21) chromosomal translocation leading to the production o f two 
fusion genes, PML / RAR-a and RAR-a/PML. While the former hybrid is transcribed 
in all APL patients, the latter is detectable in only 70% of cases. Therefore, detection 
o f PML / RA R-a fusion protein mRNA via RT-PCR technique has proved to be 
extremely important for molecular diagnosis and monitoring o f treatment response in 
APL patients. Studies have shown that ATRA should be incorporated into the front 
line o f therapy o f newly diagnosed APL (Sacchi et al., 1997).
3.2 Transplantation of Hematopoietic Cells
High-dose cytotoxic therapy with stem cell rescue (ie, bone marrow transplantation or 
BMT) is frequently the treatment o f choice for many patients with malignancies and 
nonmalignant diseases that affect blood cells (Jones R. J., 1998).
The main purpose of BMT and peripheral blood stem cell transplantation (PBSCT) 
procedures in cancer treatment is to enable the application o f very high doses of 
chemotherapy and radiation therapy to increase their effectiveness. BMT and PBSCT
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allow stem cells that were damaged by treatment to be replaced with healthy stem 
cells (http: // www. cancemews. com)
BMT is not only applied for the treatment o f leukemias and l}anphomas but also for 
the breast, lung, ovary, germ cell tumors, multiple myeloma, some primary brain 
tumors, and some head and neck cancers. Several noncancerous disorders such as 
aplastic anemia, severe combined immunodeficiency disease (SCID), thalassemia, and 
myelodysplastic sjmdromes are also being treated with BMT (http: // www. 
cancemews. com).
There are three groups of BMT. In syngeneic transplantation, bone marrow is taken 
from an identical twin. Allogeneic transplantation, in which the donor is a person 
other than the patient or an identical twin, is more common. The success of allogeneic 
transplantation depends on how closely the HLA (human leukocyte-associated 
antigens) antigens of donor’s marrow match those of the recipient’s marrow. Finally, 
in autologous transplantation, patients receive their own marrow or peripheral stem 
cells. The type o f transplant the patient receives depends on the type of disease and 
the availability of a suitable donor (http: // www. cancemews. com).
PBSCT is being used more frequently in both the autologous and allogeneic setting. 
Normally, progenitor cells are present in low quantities in circulating blood. However, 
stem cells can be recruited or mobilized into the peripheral blood circulation. The 
advent o f strategies for mobilization by the growth factors following subsequent
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harvest o f stera cells jfrom the peripheral circulation, has resulted in an increased yield 
o f stem cells. Recombinant growth factors such as GM-CSF and G-CSF are 
commonly used (Repka T., and Weisdorf D., 1998).
The two major problems in allogeneic transplantation are graft-versus-host disease 
and graft failure.
Leukemia Relapse After Allogeneic Transplantation
After successful allogeneic BMT, hematopoiesis and immunity is reconstituted from 
donor-derived cells. Leukemia relapse generally occurs in recipient-derived cells. This 
indicates that clonogenic malignant cells survived the high-dose chemoradiotherapy 
and avoided the graft versus leukemia (GVL) effect (Giralt S. A., and Champlin R. E., 
1994).
Relapse rarely occurs in donor-derived cells. The mechanisms postulated for leukemic 
transformation o f donor cells include radiation-facilitated viral leukemogenesis, 
persistence of the leukemic stimulus with de novo leukemic transformation, or transfer 
of oncogenic genetic material from host-derived leukemic cells to normal donor 
hematopoietic cells. Patients with more advanced disease have a higher relapse rate 
approaching 50 % to 70 % with T-cell depletion (Giralt S. A., and Champlin R. E., 
1994).
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Treatment of recurrent leukemia after allogeneic BMT has been associated with 
limited success. The administration of INF-a, EL-2 has been shown to reinduce 
remission in some cases o f relapsed acute leukemia and CML after allogeneic BMT. 
In cases o f relapse later than 12 months, a second transplantation may be associated 
with 20 % to 30 % long term DFS (disease free survival) (Tabbara I. A., 1996).
In addition, there are experimental treatments that include adoptive immunotherapy, 
gene therapy, and anti-sense approach.
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Bone Marrow Transplantation in Turkey
Bone marrow transplantation centers in Turkey are shown on the following map 
(Figure 10). Approximately 200 new transplantations are performed per year and 
nearly half o f them are done at Ankara University, School o f Medicine, the 
Department o f Hematology. The centers are as follows:
1 a. Ankara University, School o f Medicine, İbn-i Sina Hospital
1 b. Ankara University, School of Medicine, the Department o f Pediatrics
2 a. Hacettepe University, School o f Medicine, İhsan Doğramacı Children’s Hospital 
2 b. Hacettepe University, School of Medicine, the Department o f Hematology
3. Giilhane Medical Academy (GATA) Ankara
4. Erciyes University
5. Çukurova University
6. Akdeniz University
7. Ege University
8. Marmara University
9. Gülhane Medical Academy (GATA) Haydarpaşa
10 a. Istanbul University, Istanbul Faculty of Medicine, the Department o f Internal 
Medicine
10 b. Istanbul University, Cerrahpaşa Faculty of Medicine, the Department of Internal 
Medicine
11. Bizim Lösemili Çocuklar Vakfi
12. Tepecik Hospital
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I. 4. MONITORING OF MINIMAL RESIDUAL DISEASE IN
HEMATOLOGICAL MALIGNANCIES
4.1 The Concept of Chimerism
During the last decades, organ and BMT have given rise to individuals who are true 
artificial biologic chimera (Gosalvez et al., 1996). Chimerism is the coexistence of 
donor and recipient cells (Privitera et al., 1992). In patients with leukemia, different 
hematopoietic chimeric states may result after an allogeneic BMT (Gosalvez et al., 
1996). The patient may either exhibit mixed chimerism or complete chimerism. The 
former is the presence o f host hematopoietic cells together with donor cells while the 
latter is the complete conversion to donor’s cell type (Ozbek et al., 1997). The degree 
o f chimerism achieved after transplantation appears to have a strong influence on the 
outcome o f BMT, either in the development of GVHD, in the failure or rejection of 
stable marrow engraftments, or in the relapse o f the disease (Gosalvez et al., 1996).
4.2 Minimal Residual Disease (MRD)
The term minimal residual disease (MRD) describes leukemia cells present at a level 
below that is detectable by conventional methodology in patients being in complete 
hematological and clinical remission (CR) (Widzysska I., and Kuratowska Z., 1995).
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Clinically, MRD can be an indicator for a prediction of relapse. As an example, a 
greater MRD on entering CR tends to be related with an early relapse, a return to 
MRD-positive after disappearance o f MRD will be a sign o f impending relapse, and 
MRD negativity at the termination o f therapy may be correlated with a long-term 
DFS. Therefore, more precise evaluation o f MRD is necessary with regard to 
therapeutic strategy in monitoring of the disease (Misawa et al., 1995).
4.3 Direct Monitoring of MRD Using Chromosomal Rearrangements
The detection o f MRD has gained special significance in BMT due to the possibility 
not just to detect but also to prevent, treat and reinduce remission in patients that 
relapsed post-BMT by immunotherapy (Toren et al., 1996). During the last decade, 
several techniques have been proposed and used for detecting MRD each of which is 
characterized by advantages and limitations, mainly related to its sensitivity and 
specificity. The general limitations of such tests originates from the size of the sample 
that can be analyzed and the heterogeneous distribution of leukemia after treatment 
(Carlo - Stella e ta l,  1995).
MRD can be detected by various modem techniques such as cytogenetics, RFLP 
analysis, analysis o f VNTRs by Southern blot or PCR, microsatellite sequences, PCR 
amplification products o f the Y chromosome or the Amelogenin gene, quantitative 
PCR and FISH (Toren et a l, 1996).
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The veiy rapid development of techniques based on use o f PCR for characterization 
o f molecular lesions in leukemia and lymphoma also offers the opportunity for 
monitoring residual disease at a sensitivity o f one malignant cell in 10(5) or 10(6) 
normal cells. Maximal specificity is achieved when the DNA sequences amplified are 
leukemia specific such as BCR /  ABL in CML, PML /  RAR-a in APL, AML-1 /  ETO 
in t (8;21) in AML and CBFB /  M YH ll in inv 16 AML. A considerable level of 
sensitivity may also be achieved by using Ig heavy chain (IGH) and TCR gene 
rearrangements (Saglio G., 1995).
4.4 Indirect Monitoring of MRD Using DNA Polymorphisms
Several indirect analysis methods have been used to evaluate chimerism following 
BMT. These include protein polymorphisms, chromosomal studies and DNA typing. 
PCR has been used for the rapid and sensitive analysis of human DNA variations 
which are inlierited in a Mendelian fashion. These variations include highly 
polymorphic tandemly repetetive minisatellites and single locus polymorphisms 
(Ozbek e ta /., 1997).
Restriction fragment length polymorphisms (RFLPs) are DNA variants that are 
caused by single nucleotide polymorphisms (SNPs). Another common class o f RFLP 
is due to variable number of tandem repeats (VNTR) resulting in the restriction 
fi-agment length variability. These are called minisatellites and show extensive size
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variation with many alleles per locus. Microsatellites or dinucleotide repeats were 
identified as a subclass o f VNTRs. They show a high level of length variation and are 
distributed approximately randomly throughout the genome (Schafer et al., 1997).
Short tandem repeat (STR) loci consist o f simple tandemly repeated sequences o f 1-6 
bp in length. STRs may exhibit a high degree o f length polymorphism due to the 
variable number o f repeat units. They appear to be abundant throughout the human 
genome and occur, on average, every 6-10 kb. Polymorphic STR sequences are 
present in both intragenic and extragenic regions. Their abundance, polymorphic 
nature, and availability for amplification by PCR, make STRs ideal genetic markers. In 
addition, DNA profiling based on PCR amplification o f STRs has the advantage o f 
being more sensitive than conventional techniques (Kimpton et al., 1993).
RFLPs are usefial genetic markers for documentation o f hematopoietic chimerism 
after BMT as well as for determining the origin o f leukemic cells in BMT patients 
with recurrent disease. Amplification of multiple polymorphisms and their analysis 
provides a way to perform rapid genotyping. These amplified sequence 
polymorphisms are ideal for chimerism evaluation after BMT between sibling pairs 
because several polymorphic loci must be analyzed to achieve a high probability o f 
having at least one informative locus. The major advantage o f using PCR-based 
analysis for this purpose is increased sensitivity, thereby making it possible to detect a 
small proportion o f DNA o f donor or recipient origin. In addition, as the quality o f the 
DNA used in the analysis is less critical, abbreviated methods may be used for DNA
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preparation; only small amounts o f DNA are required, and the analysis is more rapid 
than traditional RFLP analysis (Ugozzoli et a l, 1991).
The detection o f a complete chimerism is a good prognostic factor in patients who 
undergo BMT. Although, a complete conversion to donor hematopoiesis is expected 
following allogeneic BMT, it is known that persistence or reappearance o f recipient 
hematopoiesis is not an unusual event. These recipient cells can either be malignant or 
non-malignant. The reappearance o f malignant host cells indicates relapse, while 
normal recipient cells may coexist with donor cells for various periods of time 
resulting in situations called transient or stable mixed hematopoietic chimerism 
(Suttorp cif <2/., 1993).
In this study four STR loci of tetranucleotide repeats have been used (Table 8). In 
addition to the four STR loci described, a PKU (phenylketonuria) VNTR 
polymorphism in PAH gene was also studied.
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Table 8 : Locus Specific Information of the STR Loci Studied
STR Locus
GeoBank Locus 
and Locus 
Defínition
Chromosomal
Location
Repeat Sequence 
5’ - 3 ’
Size Range 
(bases)
vWA (vWF) HUMVWFA31 12pl2 - pter AGAT 139 -167
THOl HÜMTH01 llp l5  - 15.5 AATG 179 - 203
F13A01 HUMF13A01 6p24 - 25 AAAG 283 -331
FESFPS HUMFESFPS 15q25 - qter AAAT 222 - 250
(Adapted from Gene Print™ STR Systems Promega Technical Manual)
Regarding Table 8 :
HUMVW FA31 ; Human von Willebrand factor gene 
H Ü M T H 01 : Human tyrosine hydroxylase gene 
HUMF13A01 : Human coagulation factor XIII a subunit gene 
H UM FESFPS : Human c-fes / fps proto-oncogene
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I. 5. AIM
The aim o f this thesis is the development of PCR-based tests for the diagnosis and 
also monitoring o f patients with different hematological malignancies. In this context, 
we focused on two aspects: The first one is DNA polymorphism based evaluation o f 
chimerism status o f patients following allogeneic transplantation. The second aspect is 
reverse-transcriptase polymerase chain reaction (RT-PCR) based analysis o f 
breakpoints generated by chromosomal rearrangements in various acute and chronic 
leukemias.
As research advances, the general transplantation procedures for the treatment o f 
hematological malignancies are modified. On the way to obtain the maximum survival 
rate with minimum post-operation complications, molecular studies such as the 
evaluation o f chimerism status is o f great value for the establishment of new 
therapeutic strategies. In addition, the repetitive analyses performed at different time 
intervals in post-transplantation period, is a supportive prognostic approach.
This study is also expected to provide information on the correlation o f certain 
chromosomal rearrangements with the development o f acute and chronic leukemias in 
the Turkish population. Besides, it will be the starting point for determination o f exact 
breakpoints that result in the generation of fusion transcripts.
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n. MATERIALS AND METHODS
1. MATERIALS
1.1 Patient Samples
Peripheral blood, bone marrow, and buccal wash samples were obtained from patients 
with various hematological malignancies in collaboration with Ankara University, 
School o f Medicine, İbn-i Sina Hospital, Bone Marrow Transplantation Unit, and 
Hacettepe University, İhsan Doğramacı Children’s Hospital. Either evaluation of 
chimerism status after allogeneic transplantation or fusion transcript detection was 
done using DNA or RNA analyses. Detailed information on these patients is as 
follows:
Chimerism Analysis
A total o f 22 recipient-donor pairs who underwent allogeneic PBSCT for different 
hematological diseases were evaluated for the chimerism status. The distribution o f 
the patients according to their diagnoses are as follows : Chronic myelogenous 
leukemia (CML) (n=6), acute myelogenous leukemia (AML) (n=13), [3-thalassemia 
((3-TM) (n=2), and non Hodgkin’s lymphoma (NETL) (n=l). Except for one o f the (3- 
thalassemia cases (KIT-15), which was from Hacettepe University, all the patients
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were referred from Ankara University. Among the AML patients, two o f them had 
M6 (KIT-5, KIT-11), one had M2 (KIT-14) and one had M3 (KIT-22) subtypes. One 
o f the patients (KIT-23) had MDS together with AML. Patient data, disease type, and 
sex, are summarized in Table 9.
Fusion Transcript Analysis
For the analysis o f fusion transcripts, 44 patients diagnosed with acute or chronic 
leukemias were analyzed. 20 o f the patients were female and 24 of them were male. 
17 patients were newly diagnosed, and the others underwent allogeneic BMT or 
PBSCT prior to molecular tests. There are five relapse cases (FS-2, FS-3, FS-7, FS-9, 
and FS-15), three CML patients are under IFN treatment (FS-17, FS-20, and FS-43), 
and one patient (FS-47) is under chemotherapy. O f the 44 patients, the diagnoses are 
as follows: Chronic myelogenous leukemia (CML) (n-26), acute myelogenous 
leukemia (AML) (n=14), myelodysplastic syndromes (MDS) (n=3), and acute 
lymphoblastic leukemia (ALL) (n=l). The FAB subtype diagnoses o f AML patients 
are: M l (FS-8, FS-29, and FS-46), M2 (FS-7, and FS-15), M3 (FS-1, and FS-26), 
and M4 (FS-2, FS-11, FS-21, and FS-23). One of the AML patients was diagnosed to 
have biphenotypic AML (FS-14) and the subtypes o f the remaining two patients (FS- 
18, FS-47) are unknown. One AML patient (FS-18) has been in long remission after 
the treatment. The FAB subtype diagnoses of two MDS patients are RAEB-t (FS-5), 
and RAEB (FS-6), while that o f the third patient (FS-12) is not known. Patient 
information such as diagnosis, treatment status, and sex are outlined in Table 10.
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Table 9 : Patient Samples for Evaluation of Chimerism Status After Allogeneic 
Transplantation
Case Disease Sex(D/R)
1. KIT-1 CML (Ph+) F /M
2. KIT-4 AML F / F
3. KIT-5 AML-M6 M /M
4. KIT-6 AML F /M
5. KIT-10 AML F / F
6. iaT-11 AML-M6 M /M
7. K IT-12 AML F /M
8. KIT-13 CML M /M
9. KIT-14 AML-M2 M /M
lO.KIT-15 3-TM F /F
11.K IT-16 3-TM M /M
12.KIT-17 NHL F /M
13.KIT-18 CML F /F
14.KIT-19 AML M /M
15.KIT-21 AML F /M
16.KIT-22 AML-M3 F /M
17.KIT-23 MDS + AML M /M
18.KIT-24 AML M /F
19.KIT-25 AML M /F
20.KIT-29 CML F /M
21.KIT-30 CML M /F
22.KIT-32 CML F /M
D / R: Donor / Recipient 
F: Female 
M: Male
[3-TM: P-thalassemia
CML: Chronic myelogenous leukemia 
AML: Acute myelogenous leukemia 
MDS: Myelodysplastic syndromes 
NHL: Non Hodgkin’s lymphoma
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Table 10 ; Patient Samples for Detection of Fusion Transcripts
Patient Code Sex Diagnosis Treatment
1. FS-1 F AML-Eo M3 Radiotherapy
2. FS-2 F AML-M4 Relapse
3. FS-3 M ALL Relapse
4. FS-4 M CML
5. FS-5 M MDS-RAEBt
6. FS-6 M MDS-RAEB New diagnosis
7. FS-7 M AML-M2 1994 BMT, Relapse
8. FS-8 F AML-Ml New diagnosis
9. FS-9 M CML relapse 1992 BMT, 1998 Leukocyte infusion. Relapse
10. FS-10 M Juvenile CML New diagnosis
ll.FS-11 F AML-M4 New diagnosis
12. FS-12 M MDS
13. FS-13 M CML
14. FS-14 M AML Biphenotypic New diagnosis
15. FS-15 M AML-M2 Relapse
16.FS-16 F CML New diagnosis
17. FS-17 F CML Interferon
18. FS-18 M AML Long term remission
19. FS-20 F CML Interferon
20. FS-21 F AML-Eo M4 New diagnosis
21. FS-22 F CML 1997 PBSCT
22. FS-23 F AML-M4 New diagnosis
23. FS-24 M CML
24. FS-25 F CML 1994 PBSCT
25. FS-26 M AML-M3 New diagnosis
26. FS-27 F CML New diagnosis
27. FS-28 F CML 1996 PBSCT
28. FS-29 M AML-Ml New diagnosis
29. FS-30 F CML
30. FS-31 M CML New diagnosis
31. FS-32 M CML PBSCT
32. FS-33 F CML New diagnosis
33. FS-34 F CML PBSCT
34. FS-35 M CML New diagnosis
35. FS-36 F CML
36. FS-38 F CML New diagnosis
37. FS-39 M CML 1996 PBSCT
38. FS-40 M CML
39. FS-42 F CML
40. FS-43 M CML Interferon
41. FS-44 M CML 1997 PBSCT
42. FS-45 M CML New diagnosis
43. FS-46 F AML-Ml New diagnosis
44. FS-47 M AML Chemotherapy
CML: Chronic myelogenous leukemia
AML; Acute myelogenous leukemia
PBSCT; Peripheral blood stem cell transplantation
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ALL; Acute lymphoblastic leukemia 
MDS; Myelodysplastic syndromes 
BMT; Bone marrow transplantation
1.2 Chemicals
The list of the chemicals that were used in this study is shown in Table 11: 
Table 11 : List of the Chemicals Used in This Study
ITEM SUPPLIER CATALOGUE NO
Absolute alcohol Kimetsan Kimetsan
Acetic acid (glacial) Sigma A6283
Acrylamide Sigma A9099
Agarose Sigma A9539
Ammonium chloride Sigma A9434
Ammonium persulphate (APS) Sigma A9164
Boric acid Sigma B0252
Bromophenol blue Sigma B5525
Chloroform Sigma C2432
Diethylpyrocarbonate (DEPC) Sigma D5758
EDTA (disodium salt) Sigma E5134
Ethanol, absolute Delta Bios JDEl
Ficoll Separating Solution Biochrom KG L6113
Formaldehyde Sigma F8775
Guanidine thiocynnate Sigma G6639
Glycerol Carlo Erba 453751
Hydrogen peroxide Sigma M-8600
Isoamylalcohol Sigma 19392
Isopropanol Sigma 19516
Magnesium chloride Sigma M1028
Mercaptoethanol Sigma M3158
Metaphor agarose FMC 50182
MOPS Sigma M8899
N-Laurylsarcosine Sigma L9150
N-N methylene-bis-acrylamide Sigma M2022
Formamide Sigma F7508
Phenol Sigma P1037
Potassium chloride Sigma P4504
Potassium bicarbonate Carlo Erba 359327
Potassium phosphate (monobasic) Sigma P5379
Lauryl sulphate (SDS) Sigma L5750
Silver nitrate Sigma S8157
Sodium acetate Sigma S2889
Sodium chloride Sigma S3014
Sodium citrate (trisodium) Sigma S4641
Sodium hydroxide Sigma S0899
Sodium phosphate (dibasic) Sigma S3264
TEMED Sigma T8133
Tri Reagent Sigma T9424
Tris base Stratagene 300174
Urea Sigma U5378
Xylene cyanol Sigma SX4126
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1.3 Equipment
The following equipment were used in this study :
1. Aerosol resistant filter (lOOul, 200ul, lOOOul), US patent #5364595
2. Balance (Shimad2ai Libror EB-2200HU, Shimadzu Libror AEG-120)
3. Black and White Monitor (SSM-121CE)
4. Centrifuge (Beckman GS-15R)
5. E-C Electrophoretic Gel System (MiniCell EC 370M, MidiCell EC 350M, 
MaxiCell EC 360M)
6. Fluoroscope (Vilber Lourmat)
7. Magnetic stirrer (Thermolyne)
8. Microflige (Heraeus Bioflige)
9. Millipore Milli-Q Plus PF Ultra-Pure Water System
10. Microwave oven
1 l.Oligo Synthesizer (Beckman Oligo lOOOM DNA Synthesizer)
12. PAGE Apparatus (Bio-Rad Protean® II xi Cell)
13. pH M eter (Consort P501)
14. Pipette Set :P20, P200, P I000 (Eppendorf Research)
15. Plasticware (Pipette tips, eppendorfs, 15 ml and 50 ml falcon tubes) (Costar)
16. Power supply (Bio-Rad Power PAC 200, EC 250-90)
17. Shaker (Thermolyne Roto Mix Type 50800)
18.Sony, U PP-110 Paper
19. Spectrophotometer (Beckman DU 640)
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20.Stuart Scientific test tube heater SHTl
21. Thermal Cycler (Perkin Elmer 9600, MJ Research PTC-200)
22. UV Transilluminator (Herolab)
23. Video graphic printer (Sony, UP-890CE)
24. Vortex (Thermolyne Type 16700 Mixer)
25. Water Bath (nüve BM 402)
1.4 Others
Taq Polymerase
The enzyme Thermus aquatus DNA Polymerase (native without BSA) was from MBI 
Fermentas (EP 0282) and was supplied with lOx PCR Buffer and MgCl2 Solution. 
dNTP Mix (lOmM solution) was also from MBI Fermentas (R 0192).
First Strand cDNA Synthesis Kit
The kit used for the synthesis o f first strand o f cDNA was purchased from MBI 
Fermentas (K1612).
Components o f the kit are as follows :
MuLV-RT : Moloney murine leukemia virus reverse transcriptase 
RNAsin ; Ribonuclease inhibitor 
5x Reaction Buffer
lOmM dNTP Mix
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Oligo (dT) Primer 
Random Hexamer Primer 
Control RNA 
Control Primer
Deionised water, nuclease free
Proteinase К
Boehringer Mannheim, (1529307) enzyme was used.
Size Markers
\. pGEMMarker (Promega, G 1741)
The pGEM marker consists of 15 fragments o f the following sizes in base pairs : 
2645, 1605, 1198, 676, 517, 460, 396, 350, 222, 179, 126, 75, 65, 51, 36.
2. 100 bp DMA Ladder (MBI Fermentas, SM0241)
The marker yields the following 11 discrete fragments in base pairs : 1000, 900, 800, 
700, 600, 500, 400, 300, 200, 100, 80.
3. 1 kb DNA Ladder (MBI Fermentas, SM0311)
The marker yields the following 14 discrete fragments in base pairs : 10000, 8000, 
6000, 5000, 4000, 3500, 3000, 2500, 2000, 1500, 1000, 750, 500, 250.
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4. (f>X 174 DNA / Hinfl Marker (MBI Fermentas, SM0261)
Hinfl digest o f (f)X 174 DNA yields the following 21 discrete fragments in base pairs : 
726, 713, 553, 500, 427, 417, 413, 311, 249, 200, 151, 140, 118, 100, 82, 66, 66, 48, 
42, 40, 24.
1.5 Oligonucleotides
The primers used in this study were all synthesized in the Beckman Oligo lOOOM 
DNA Synthesizer in house, except for the PAH-VNTR primers which were kindly 
provided by Professor Meral Özgü9 from Hacettepe University. The sequences and 
the other related information are summarized in Table 12.
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Table 12 : Primers Used in This Study
Primer Code Gene
TC-22 F 
TC-23 R 
TC-24 F 
TC-25 R 
TC-26 F 
TC-27 R 
TC-28 F 
TC-29 R 
TC-66 F 
TC-67 R 
GA-111 R 
GA-112 R 
GA-431 F 
GA-114 F 
GA-113F 
GA-117 F 
GA-118R 
GA-119F 
GA-120 F 
GA-121 R 
GA-122 R 
GA-123 F 
GA-124 F 
GA-128 F 
GA-125 R 
GA-126 R 
GA-127 R 
GA-129 F 
GA-131 R 
GA-130 R 
GA-132 F 
GA-133 R 
GA-134 F 
GA-135 R 
GA-136 F 
GA-138 F 
GA-137 R 
GA-139 R 
PAH F 
PAHR____
HUMVWFA31
HUMVWFA31
HUMTHOl
HUMTHOl
HUMF13A01
HUMF13A01
HUMFES/FPS
HUMFES/FPS
P-ACTIN
p-ACTIN
C-ABL
C-ABL
C-ABL
BCR
BCR
P-ACTIN
P-ACTIN
MYL
MYL
RAR-a
RAR-a
CBFB
CBFB
CBFB
MYHII
MYHIl
MYHII
E2A
E2A
PBXl
ALL-1
ALL-1
ALL-1
AF-4
AMLl
AMLl
ETO
ETO
PAH
PAH__________
Sequence (5’ - 3’)
CCCTAGTGGATGATAAGAATAATC
GGACAGATGATAAATACATAGGATGGATGG
GTGGGCTGAAAAGCTCCCGATTAT
GTGATTCCCATTGGCCTGTTCCTC
ATGCCATGCAGATTAGAAA
GAGGTTGCACTCCAGCCTTT
GGGATTTCCCTATGGATTGG
GCGAAAGAATGAGACTACAT
TGATATCGCCGCGCTC
CAGTCAGGTCCCGGCC
TGTGATTATAGCCTAAGACCCGGA
TCCACTGGCCACAAAATCATACAGT
TTCAGCGGCCAGTAGCATCT
ATGGCGAGGGCGCCTTCCAT
GTGAAACTCCAGACTGTCCACAGCCA
CCTTCCTGGGCATGGAGTCCTG
GGAGCAATGATCTTGATCTTC
AGCTGCTGGAGGCTGTGGACGCGCCGGTACC
AGTGTACGCCTTCTCCATCA
CCACTAGTGGTAGCCTGAGGACT
CAGAACTGCTGCTCTGGGTCTCAAT
GATGCCGCGCGTCGTCCCGGACCA
AAGCGGCCGCTGAGGGCGGGAAGATGC
CAGGCAAGGTATATTTGAAGG
CTCCTCTTCTCCTCATTCTGCTC
GTCTGTGTTATCTGGAAAGGCTG
CGTACTGCTGGGTGAGGTTCT
TGCACAACCACGCGGCCCTC
CTTCTCCTCCTCCGAGTGGT
CGCCACGCCTTCCCCTAACA
CGCCCAAGTATCCCTGTAAAAC
CTTAAAGTCCACTCTGATCCT
GAGGATCCTGCCCCAAAGAAAAG
TGAGCTGAAGCTGGTCTTCGAGC
AGCCATGAAGAACCAGG
TACCACAGAGCCATCAAA
AGGCTGTAGGAGAATGG
GTTGTCGGTGTAAATGAA
GCTTGAAACTTGAAAGTTGC
GGAAACTTAAGAATCCCATC________________
Reference
Kimpton e t al. 
Kimpton e t  al. 
Kimpton e t al. 
Kimpton e t al. 
Kimpton e t al. 
Kimpton e t al. 
ICimpton e t al. 
Kimpton e t al.
Frenoy e t al. 
Frenoy e t al. 
Frenoy e t al. 
Frenoy e t al. 
Frenoy e t al. 
Biondi e t at. 
Biondi e t at. 
Biondi et at. 
Biondi et at. 
Biondi e t at. 
Biondi et at. 
Claxton e t al. 
Claxton e t al. 
Claxton e t al. 
Claxton et al. 
Claxton e t al. 
Claxton et al. 
Privitera et al. 
Privitera e t al. 
Privitera e t al. 
Cimino et al. 
Cimino e t al. 
Cimino e t al. 
Cimino e t al. 
Downing et al. 
Downing et al. 
Downing e t al. 
Downing e t al. 
Goltsov e t al. 
Goltsov e t al.
F : Forward primer R : Reverse primer
66
1.6 Solutions
1.6.1 General Stock Solutions
40 % Acrylamide (IL)
380 g acrylamide
20 g N,N-methylenebisacrylamide
is dissolved in 600 ml ddH20 and the volume is completed to IL.
0.5M EDTA  (pH; 8.0) (IL)
186.1 g disodium ethylenediaminetetraacetate.2H20 is dissolved in 800 ml H2O. 
pH is adjusted to 8.0 with NaOH (20 g pellets), and the volume is completed to IL. 
(Sambrook et al. Vol 3; B.9-B.14)
1.6.2 Buffers
Phosphate-buffered saline (PBS) (lOx, IL^
80g NaCl
2 g K C l
11.5 eNa2HP04.7H20
2 g KH2PO4
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20xSSC
3M N aCl(175g/L)
0.3 M  Na3citrate.2H20 (88g/L) 
pH is adjusted to 7.0 with IM  HCl
TBE Electrophoresis Buffer IL)
108 g Tris base 
55 g boric acid 
40m l0 .5M  EDTA, pH;8.0
TE Buffer {pH: 8.0) (lOx, IL)
lOmM Tris.Cl, pH: 8.0
ImM EDTA, pH: 8.0
(Ausubel et al. Vol 2: Appendix 2, A.2.3)
1.6.3 DNA Isolation Solutions
10 % SDS
10 g sodium dodecyl sulphate is dissolved in ddH20  and the volume is completed to 
100 ml.
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TrisHCl (0.5M,pU: 8.0)
3.94 g TrisHCI is dissolved in 40 ml dd H2O, pH is adjusted to 8.0, and the volume is 
completed to 50 ml.
Phenol: Chloroform : Isoamylalcohol (25 : 24 : 1)
25 ml phenol 
24 ml chloroform 
1 ml isoamylalcohol
Extraction Buffer
lOm M  TrisHCI pH; 8.0 
lO m M ED TA pH : 8.0 
0.5 % SDS
Sodium Acetate (3M, pH: 5.2)
40.8 g sodium acetate is dissolved in 80 ml ddH20, pH is adjusted to 5.2 with glacial 
acetic acid and the volume is completed to 100 ml.
WBCL (White Blood Cell Lysis) Buffer
m niM N H U Cl 
0,9mMNH4HCO4 
pH: 6.5
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For 10 m l: 0.01 g SDS
1.5 ml IM NaCI 
0.5 ml 0.5 M E D IA
500 fj.1 Proteinase K (from 20 ng/p.1 stock) 
The volume is completed to 10 ml with ddH20.
SM NaCl
292 g NaCl in IL ddH20.
Isoamylalcohol/ chloroform (I : 24)
1 ml isoamylalcool 
24 ml chloroform
CVS (Chorionic Villus Sampling) Buffer
1,6.4 Agarose Gel Electrophoresis Solutions
6x Loading Buffer
0.25 % bromophenol blue 
0.25 % xylene cyanol FF 
30 % glycerol in water
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5x Formaldehyde - Gel Running Buffer (IL)
20.6 g MOPS is dissolved in 800 ml DEPC-treated 50 mM sodium acetate and the pH 
is adjusted to 7.0 with 2N NaOH. 10 ml of DEPC-treated 0.5M EDTA (pH: 8.0) is 
added. The volume is adjusted to IL with DEPC-ddH20. The buffer yellows with age, 
if it is exposed to light or is autoclaved.
Formaldehyde - Gel Loading Buffer
50 % glycerol 
1 mM EDTA (pH: 8.0)
0.25 % bromophenol blue 
0.26 0.25 % xylene cyanol FF
O.IM Ammonium acetate (For staining of the gel)
7.7 g ammonium acetate in 1 L DEPC-ddH20 
(Sambrook et al. Vol 1: 7.43 - 7.45).
1.6.5 Polyacrylamide Gel Electrophoresis Solutions
12% Denaturing Gel Solution
15 ml 40 % acrylamide solution, 21 gr urea and
5 ml 1 Ox TBE are dissolved and the volume is completed to 50 ml with ddH20. 
150 pi 10 % APS and 50 pi TEMED are then added.
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950 |il formamide 
40 til 0.5 M  EDTA 
6 ddH20
2 |il 2.5 % bromophenol blue 
2 |il 2.5 % xylene cyanol
2x Loading Buffer
1.6.6 Silver Staining Solutions 
Fixative Solution
10 % ethanol and 0.5 % acetic acid (glacial)
Staining Solution
0.1 % AgN03
Developer Solution 
0 .1%  formaldehyde
1.5 % N aO H
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1.6.7 RNA Isolation Solutions
Solution D
4M Guanidium thiocyanate 
25 mM Sodium citrate (pH: 7.0)
0.5 % Sarcosyl 
0. IM  mercaptoethanol
This solution can be stored at room temperature for 3 months without 
mercaptoethanol. The addition o f this reagent drops the shelf life to 1 month.
DEPC-ddH20
1 ml DEPC is dissolved in IL ddH20, the solution is stirred in the hood overnight and 
then is autoclaved.
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2. M ETH O D S
2.1 DNA Isolation From Whole Blood
Blood sample is aliquoted and is frozen in 700 pi aliquots. Prior to the isolation
procedure, it is thawn, 800 pi lx SSC is added .mixed and spinned in a microfuge for
1 minute. 1.4 ml supernatant is removed and discarded. Following the addition o f 1.4
ml lx  SSC, it is briefly vortexed and centrifuged for 1 minute after which all the
supernatant is discarded avoiding the pellet. 800 pi Extraction Buffer and 10 pi
Proteinase K (20 mg/pl) are then added. After a brief vortex, the mixture is incubated
overnight at 56°C.The next day, in a fume hood, 400 pi phenol / chloroform /
isoamylalcohol (25: 24: 1) solution is added and vortexed for 1 minute. After spinning
for 5 minutes in a microflige, the upper aqueous layer (~ 700 pi) is removed and
placed in a new tube. This step is repeated with 350 pi phenol / chloroform /
isoamylalcohol solution until a clear interphase is obtained. The upper aqueous layer
containing DNA is separated into two tubes (350 pi per tube) and 35 pi 3 M sodium
acetate (pH:5.2) and 700 pi cold absolute ethanol are added to each tube. Tubes are
mixed by inversion and are placed at 20°C for 30 minutes. After spinning for 15
minutes in a microfuge, the alcohol is removed and the pellet is washed with 1 ml 70
% ethanol at room temperature. Following a final spin for 5 minutes, the alcohol is
removed with a micropipette and the tubes are left open on the bench for about 30
minutes for the evaporation of ethanol. Finally the DNA is resolubilized in 200 pi
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of TE buffer (pH:8.0) by incubating at 56°C at least for 1 hour. This incubation can be 
done overnight when it is necessary to solubilize the pellet. The DNA samples are 
stored at -20°C.
2.2 DNA Isolation From Buccal Wash
Buccal wash sample is placed in 15 ml falcon tube and is centrifuged at 2500 rpm for 
15 minutes. The supernatant is discarded and the pellet is dissolved in 500 pi WBCL 
Buffer by pipetting. The solution is then transferred to an eppendorf After the 
addition of 13 pi 10 % SDS and 15 pi Proteinase K, the sample is incubated at 56°C 
overnight. The next day, 16.7 pi 5 M NaCl and 520 pi isoamylalcohol / chloroform (1 
: 24) solution are added and centrifugation is applied at 13000 rpm for 10 minutes. 
Then, the supernatant is placed into a new tube and isoamylalcohol / chloroform (1 : 
24) solution is added in 1:1 volume ratio. The sample is centrifuged at 13000 rpm for 
10 minutes. This isoamylalcohol / chloroform extraction step is repeated once more 
and then, the supernatant is placed into another tube and isopropanol is added in twice 
the volume (1 :2). Following centrifugation at 13000 rpm for 10 minutes, the sample 
is washed with 500-1000 pi 70 % ethanol. After a final centrifugation for 10 minutes, 
the supernatant is discarded, 50 pi TE buffer is added and the tube is incubated at 
56°C for 1-2 hours to solubilize the pellet. The DNA sample is stored at -20°C.
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In a sterile petri dish, the biopsy sample is rinsed three times with cold lx  PBS buffer. 
Blood and debri is removed with the help o f a razor. It is then chopped into small 
pieces, taken into an eppendorf and 500 pi CVS buffer is added. The mixture is 
incubated at 56°C overnight. The following steps o f the extraction procedure is the 
same as described above in section 2.1.
2.3 DNA Isolation From Skin Biopsy
2.4 Polymerase Chain Reaction (PCR)
PCR is a technique for the in vitro amplification of specific DNA sequences by the 
simultaneous primer extension of complementary strands of DNA. There are 3 major 
steps in the reaction which are dénaturation, annealing o f primers and extension 
(synthesis). The requirements of the reaction are deoxynucleotides to provide both the 
energy and nucleosides for the synthesis of DNA, DNA polymerase, primer, template, 
and buffer containing magnesium. The deoxynucleotides and primers are present in 
excess, so the synthesis step can be repeated by heating the newly synthesized DNA 
to separate the strands and cooling to allow the primers to anneal to their 
complementary sequences. The heating and cooling cycles can be repeated and DNA 
will continue to accumulate exponentially until one of the reaction components are 
exhausted or the enzyme is unable to synthesize new DNA quickly enough. The 
number o f cycles required for optimum amplification varies depending on the amount
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of starting material and the efficiency o f each amplification step (Me Pherson et a l, 
1991).
For the evaluation o f chimerism status, 93 DNA samples which belong to 22 
recipient-donor pairs were analyzed by PCR at 4 genomic STR loci (HUMVWA31, 
HUM THOl, HUMF13A01, and HUMFES / FPS) and one PAH VNTR locus. Primer 
information is given above in Table 12. PCR reactions were performed in an 
automated thermal cycler (Perkin Elmer 9600).
Preparation of Reaction Mixture
The components o f the reaction mixture and their amounts in 50 pi reaction volume 
are summarized in Table 13.
Table 13 : The Components of PCR Reaction Mixture
Reagent
Sterile ddH^O 
lOx PCR Buffer 
dNTP Mix (10 mM each) 
Primer I
Primer II
Tag Polymerase ( 4 u /  pi)
MgCh ( 2 5 mM)
Template (DNA ) ______
Final
Conce i^Rration
lx
0.2 mM 
25 pmol
25 pmol 
1.2 u 
1.5 mM 
variable
Quantity for 50 pi 
mixture
variable 
5 pi
1 pi
Variable ( 1 pi)*
0.30 pi 
3 pi
2 pi
* The primer working solutions were prepared as 25 pmol / pi.
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Amplification Conditions
The amplification conditions and the number of cycles for STR and PAH VNTR 
analyses are the following :
STR  : 95°C 5 min / 94“C 1 min - 54°C 1 min - 72°C 1 min (10 cycles) / 90°C 1 min - 
54°C 1 min - 72°C imin (20 cycles) / 72°C 10 min.
PAH VNTR : 94°C 5 min / 94°C 30 sec. - 54°C 30 sec - 72°C 30 sec (30 cycles) /
72“C 5 min.
2.5 Agarose Gel Electrophoresis
Agarose gel electrophoresis is a simple and highly effective method for separation, 
identification, and purification o f DNA fragments. The procedure can be divided into 
three stages :
1. A gel is prepared with an appropriate agarose concentration for the size of DNA 
fragments to be separated.
2. DNA samples are loaded into the sample wells and the gel is run at a voltage and 
for a time period to achieve optimal separation, and
3. The gel is stained, or if ethidium bromide is incorporated into the gel and 
electrophoresis buffer, it is visualized directly upon illumination with UV light.
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Agarose concentration, applied voltage, electrophoresis buffers, and DNA 
conformation are among the parameters that affect the migration o f DNA through 
agarose gels (Ausubel etal., Vol 1; 2.5.1-2.5.9).
Isolated DNA samples and amplification products were run on agarose gels, 1.2 % 
and 2 (also 3 and 4) % gels were prepared respectively and 5 pi DNA or 5 pi 
amplification products were mixed with one volume loading buffer and were loaded 
onto gels. The gels were run in lx  TBE running buffer at voltages between 80V and 
lOOV for different time intervals (30 min - 60 min). Standard DNA markers, 100 bp 
DNA ladder and <|)X175 Hinfl were used to estimate the sizes of the fragments. The 
gels were stained further with ethidium bromide when necessary , were visualized 
under UV light and photographed.
2.5.1 MetaPhor Agarose Gel Electrophoresis
The procedure is as described by the manufacturer. MetaPhor agarose is weighed 
according to the percentage and the amount o f the gel. A beaker or flask that is 2.5 - 
4 times the volume o f the final agarose solution should be preferred. Chilled lx  TBE 
is added with a stir bar and the solution is slowly stirred to prevent the formation o f 
lumps. The stir bar is removed, the flask is covered with plastic wrap, and a small hole 
is pierced as a steam vent. The solution is placed in a microwave oven which is 
adjusted to medium power. The solution is heated using several 20-60 sec intervals
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and swirling is done between pulses. This heating-swirling cycles are done till agarose 
is completely dissolved. Then, plastic wrap is removed and warm deionised water is 
added to obtain initial volume o f solution and is mixed. The solution is cooled to 
60°C-70°C before pouring. The gel is left for polymerization at room temperature for 
30 minutes and at 4°C for 30 minutes more. Finally the samples are loaded and the gel 
is run. It can be run at room temperature.
2 % metaphor agarose gel was prepared for the separation o f STR alleles and the gel 
was run at lOOV for 4 hours, stained with 1 pg/ml ethidium bromide solution for 40 
minutes and destained with deionised water for 1 hour.
2.5.2 Formaldehyde - Agarose Gel Electrophoresis
The gel is prepared by melting the appropriate amount of agarose in water, cooling it 
to 60°C. 5x formaldehyde-gel running buffer and formaldehyde are added to give final 
concentrations of lx  and 2.2M, respectively. In order to achieve these concentrations, 
one part of a stock 12.3 M formaldehyde solution is diluted with 3.5 parts of agarose 
in water and 1.1 parts o f 5x formaldehyde gel running buffer. The gel is casted in a 
chemical hood because formaldehyde vapors are toxic. The gel is allowed to set for at 
least 30 minutes at room temperature. Then the samples are prepared by mixing the 
following in a sterile microfiige tube:
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RNA (up to 30 pg)
5x formaldehyde gel-running buffer
Formaldehyde
Formamide
4.5 pi
2.0 pi
3.5 pi
10.0 pi
The samples are incubated for 15 minutes at 65°C,and they are chilled on ice. Then, 2 
pi o f sterile DEPC-treated formaldehyde gel-loading buffer is added. Before loading 
the samples, the gel is prerun for 5 minutes at 5 V/cm. The gel is loaded and run in lx  
formaldehyde gel-running buffer at 3-4 V / cm. When the bromophenol blue migrates 
approximately 8 cm the run is ended (Sambrook et a l, Vol 1: 7.43-7.45).
1.2 % gel was prepared, run at 50V for 5 hours, and then was stained with ethidium 
bromide (0.5 pg/ml) in O.IM ammonium acetate for 30-45 minutes.
2.6 Polyacrylamide Gel Electrophoresis (PAGE)
PAGE offers high resolution of low-molecular weight nucleic acids. A polyacrylamide 
gel is formed by the polymerization of acrylamide monomers into long chains, which 
are further covalently attached by a cross-linking agent N ’N-methylene-bisacrylamide. 
Polymerization reaction is initiated by free radicals provided by APS and stabilized by 
TEMED. The pore size o f a polyacrylamide gel is determined by the total percentage
o f aciylamide (Ausubel et al., Vol 1: 2.7.1-2.7.5).
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Amplified products are electrophoressed through 8-12 % denaturing polyacrylamide 
gel. The procedure is as follows;
50 ml o f 12% denaturing gel solution is prepared and poured. The gel is allowed to 
polymerize for at least 1 hour and is then prerun at 90V for 30-60 minutes. The 
samples are mixed with 2x loading buffer in 1:1 volume ratio and are denatured at 
95°C for 10 minutes. Then they are chilled on ice and are loaded onto the gel. The gel 
is run in lx  TBE running buffer at 90-100V for 18-20 hours and is silver stained.
2.7 Silver Staining
After the electrophoresis, the gel clamps are loosen and the glass plates are removed 
from the apparatus. The gel is placed in a plastic tray and is rinsed twice in ddH20 for 1 
minute. Then the gel is incubated in 300 ml of fixative solution for 3 minutes. The 
solution is discarded and the gel is treated with 300 ml of fresh fixative solution for the 
second time for 3 minutes. After rinsing with ddH20, the gel is incubated in 300 ml of 
0.1 % AgNOs solution for 10 minutes at room temperature. Following this staining 
step, the gel is rinsed twice in ddH20 rapidly. Finally 300 ml of ice-cold developer 
solution is added and the gel is incubated in this solution till the bands develop. 
Formaldehyde should be added just before the use of the solution. The development 
takes about 40 minutes. Then the developer solution is discarded and the gel is placed 
in 7.5 % acetic acid solution to stop the reaction. The gel is sandwiched between two 
transparency sheets for storage.
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2.8 White Blood Cell Separation with Ficoll Centrifugation
In a 15 ml falcon tube, 2 ml bone marrow or peripheral blood sample is mixed with 2 
ml lx  PBS buffer and is mixed gently by inversion. In another tube, 4 ml Ficoll 
separating solution is placed and the sample - PBS mixture is layered carefully on 
Ficoll. The sample is centrifuged at 2000 rpm for 30 minutes. The interphase is 
removed gently and is placed in a new tube. 5 ml lx  PBS is added, mixed and 
centrifuged at 1200 rpm for 7 minutes. This washing step can be repeated if necessaiy. 
After the centrifugation the pellet is kept in 1 ml Solution D and is stored at -80°C for 
further use.
2.9 RNA Isolation Using TRI Reagent
One o f the most important aspects in the isolation o f RNA is to prevent any 
degradation o f RNA during the isolation procedure. Some agents that are used to 
preserve RNA integrity during extraction are summarized in Table 14.
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Table 14: Agents Used to Preserve RNA Integrity During Extraction
Agent Method of Ribonucléase Inactivation
DEPC
Guanidium thiocyanate 
Phenol / chloroform
Alkylates proteins, disrupting protein structure
Denatures proteins
Extracts and denatures ribonucleases
(Adapted from Jones et al., 1994)
TRI Reagent is a mixture of guanidine thiocyanate and phenol in a mono-phase 
solution which enables the simultaneous isolation o f RNA, DNA, and proteins. RNA 
isolation procedure using TRI reagent is of 2 stages: sample preparation, and RNA 
isolation. The procedure is as described by the manufacturer.
Sample Preparation:
500 p.1 o f sample (WBC preparation kept in Solution D, bone marrow or peripheral 
blood samples can be used directly as well) is mixed with 1 ml TRJ reagent and a 
homogeneous lysate is formed by pipetting. It is centrifiiged at 12000 rpm for 10 
minutes at 4°C. The supernatant contains RNA and proteins. The clear supernatant is 
transferred to a new tube and is allowed to stand for 5 minutes at room temperature. 
Then, 200 |i.l o f chloroform is added per ml of TRI reagent used, is shaked vigorously 
for 15 seconds and is allowed to stand at room temperature for 2-15 minutes. The 
centrifugation step at 12000 rpm for 15 minutes at 4°C separates the mixture in 3 
phases;
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i. red organic phase protein
ii. interphase DNA
iii. colorless upper aqueous phase RNA
RNA Isolation:
The upper aqueous phase is transferred to a new tube,500 pi isopropanol is added per 
ml o f TRI reagent used and is mixed. The sample is allowed to stand for 10 minutes at 
room temperature and then it is incubated at 4°C overnight. The next day, it is 
centrifuged at 12000 rpm for I j  minutes at 4°C. RNA precipitate forms a pellet on the 
side and bottom o f the tube (interphase and organic phase can be stored at 4°C for 
subsequent DNA and protein isolation). The supernatant is removed and the RNA 
pellet is washed with 1 ml 75 % ethanol per ml o f TRI reagent used. The sample is 
then vortexed and centrifuged at 7500 rpm for 5 minutes at 4°C. If RNA pellet floats, 
the wash is performed in 75 % ethanol at 12000 rpm for 10 minutes. The supernatant 
is discarded and the pellet is briefly dried for 5-10 minutes by air drying or under a 
vacuum. It is important not to overdry the pellet as this will greatly decrease its 
solubility. The usage of Speed-Vac is not recommended. Finally, an appropriate 
amount (50 |il) formamide, DEPC-water or 0.5 % SDS solution is added to the RNA 
pellet. To facilitate dissolution, repeated pipetting is applied at 55-60°C for 10-15 
minutes. The isolated RNA sample can be kept at -20°C or -80°C.
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For the isolation procedure, WBC preparation is used and is observed to give better 
results than bone marrow and peripheral blood. RNA pellet is dissolved in DEPC- 
ddH20 and is kept at -80°C. After the isolation, the concentration o f the samples were 
determined by spectrophotometric measurements. It has been stated that the 260 / 280 
OD ratio o f the RNA preparation should be no less than 1.7. The integrity o f the 
isolated RNA samples is also checked by electrophoresis through 1.2 % gels 
containing formaldehyde.
2.10 First Strand cDNA Synthesis
Synthesis o f first strand cDNA that is suitable for PCR amplification was performed 
with MBI Fermentas kit. The procedure is described by the manufacturer as follows:
For a total reaction volume of 20 ul;
The following reaction mix is prepared in a tube on ice;
Template RNA
Total RNA
or
Poly A RNA
or
Specific RNA
1-5 pg
0.1-0.5 pg
0.01 pg-0.5 pg
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• Primer
Random hexamer (0.2 jig / jj.1) 1 p,l
or
OligodT Primer (0.5 |ag / |il) 1 |il
Sequence specific 15-20 pmol
• dd H 2 O, nuclease free up to 11 pi
This mixture (maximum volume should be 11 pi) is mixed gently and spinned down in 
a microfiage. It is then incubated at 70°C for 5 minutes, chilled on ice and the drops 
are collected by brief centrifugation. The tube is placed on ice and the following 
components are added in the indicated order;
• 5x reaction buffer 4 pi
• Ribonucléase inhibitor (20 u / pi) 1 pi
• 10 mM dNTP mix 2 pi
This mixture is mixed gently and spinned down in a microfuge. The next is the 
incubation at 37°C for 5 minutes. If random hexamer is used, the incubation is at 25°C 
for 5 minutes. Then,
M -M uLVRT(20 u / pi) 2 pi
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is added and the total volume becomes 20 ^1. The mix is incubated at 37°C for 60 
minutes. If  random hexamer is used, it is incubated at 25°C for 10 minutes first and 
then at 37°C for 60 minutes. Finally, the reaction is stopped by heating at 70°C for 10 
minutes. The sample is chilled on ice. The synthesized cDNA is stored at -20°C and it 
can directly be used for amplification by PCR.
In this study, total RNA that is isolated by TRI reagent was used as template and it 
was primed by random hexamer primers. The protocol was followed accordingly.
2.11 Reverse Transcriptase - Polymerase Chain Reaction (RT-PCR)
Problems with PCR arise especially when dealing with poor quality or low-copy 
number nucleic acid template. Using nested PCR (nPCR) or nested RT-PCR (nRT- 
PCR), the sensitivity and specificity o f both DNA and RNA amplification is 
considerably improved. The process utilizes two consecutive PCRs. The first PCR 
contains an external pair of primers, while the second contains two nested primers 
which are internal to the first primer pair, or one o f the first primers and a single 
nested primer (half nested PCR). The larger fragment produced by the first reaction is 
used as template for the second PCR (Me Pherson et al., 1991).
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For the detection o f fusion transcripts, a panel was prepared regarding the type o f the 
malignancy and the chromosomal rearrangements that are expected. The RT-PCR 
analyses were done according to this panel which is summarized in Table 15. A total 
o f translocations and 1 inversion were studied which are;
1 . t(9;22) (q34;q ll)
2. t (8;21) (q22;q22)
3. t(15;17)(q22;q21)
4. t(4 ;ll)(q 2 1 ;q 2 3 )
5. t(l;19)(q23;p23)
6. inv 16 (pl3;q22)
Table 15: Panel For RT-PCR Analysis
Chromosomal R earrangem ent
Disease N um ber of Patients Analyzed
CM L...... . .... ..........' ”'26............ ............t'(9;22)
AM L 14 t(9;22), t(8 ;21),t(15 ;17), inv 16
MDS 3 t (9;22), t (8;21), t (15;17), t (4;11), t (1;19), inv 16
ALL 1 t(9 ;2 2 ) , t (4 ; l l ) , t ( l ;1 9 )
Preparation o f Reaction Mixture
The components o f the reaction mixture and their amounts in 30 pi reaction volume 
are summarized in Table 16. Detailed primer information is given in Table 12.
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Table 16: The Components of RT-PCR Reaction Mixture
Reagent Final
Concentration
Quantity for 30 
|il mixture
Sterile ddH20 - variable
lOx PCR Buffer lx 3 pi
DNTP M ix (10 mM  each) 0.2 mM 0.6 pi
Primer I 20 pmol
Variable ( 1 pi)*
Primer II 20 pmol
Taq Polymerase ( 4 u / pi) l.O u 0.25 pi
MgCh ( 2 5 m M ) 1.5 mM 1.8 pi
Template (cDNA/1^ PCR Product )____ variable 4 pi
* The primer working solutions were prepared as 20 pmol / pi.
Amplification Conditions For Each Analysis 
t(9;22) (q34;qll):
f  PCR : 94°C 2 min / 93°C 3 min - 65°C 2 min - 72°C 3 min (30 cycles) / 65°C 2 min
- 72°C 15 min (1 cycle)
2 nd 2 nun / 93°C 2 min - 65°C 1 min - 72°C 2 min (30 cycles) / 65°C 1 min
- 72°C 15min(l cycle)
t(8;21) (q22;q22):
1^ ' PC.R and 2"‘‘ PCR : 94°C 2 min - 55°C İmin - 72°C 1 min (1 cycle) / 94°C 1 min -
55°C İmin - 72°C 1 min (14 cycles) / 94°C 1 min - 55°C İmin - 72°C 2 min (24 cycles)
/ 94°C 1 min - 55°C İmin - 12°C 7 min (1 cycle)
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t (15; 17) (q22;q21):
PC.R and 2'“^ PCR : 95°C 5 min / 95°C 1 min - 55°C İmin - 72°C 1 min (30 cycles) 
t (4 ; ll)  (q21;q23):
I"“ PCR and 2'“' PCR : 94°C 2 min / 94°C 1 min - 56°C İmin - 72°C 1 min (30 cycles) 
t (1;19) (q23;p23): (Single PCR)
94°C 2 min / 94°C 30 see - 62°C 30 see - 72“C 30 see (40 cycles) 
inv 16 (pl3;q22):
r ‘PCR and2”‘‘PCR : 95°C 5 min / 94°C 1 min - 58°C İmin - 72“C 1 min (45 cycles)
Beta-aetin gene was amplified to check the integrity of the cDNA samples. The 
amplification was both performed at separate tubes and in the same tube with each of 
the above analyses. The amplification condition as a separate reaction is as follows.
Beta-Actin (TC66 - TC67) :
95°C 3 min / 94°C 1 min - 60°C İmin - 72“C 1 min (30 cycles)
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m . RESULTS
1. Evaluation of Chimerism with DNA Polymorphisms After Allogeneic 
Transplantation
In this study, polymorphic DNA markers, four STR and one PAH VNTR 
polymorphisms, were used to evaluate the chimeric status o f 22 donor-recipient pairs 
after allogeneic transplantation. For this purpose, genomic DNA was isolated from 
buccal wash, and peripheral blood samples (also skin biopsy sample o f one patient, 
KIT-4) of recipients and peripheral blood samples o f donors. Then, PCR amplification 
was performed with specific STR and PAH primers. The amplified products were run 
on denaturing polyacrylamide gels and silver stained for visualization. Genotype 
analysis was done at intervals ranging from 15 to 2920 days post-transplantation. The 
original genotype (pre-transplantation) o f the recipient was determined from buccal 
wash samples. The post-transplantation genotype of the recipient and the original 
genotype of the donor were determined from peripheral blood samples. The 
chimerism status is determined by comparison of the recipient’s post-transplantation 
genotype with the pre-transplantation genotype and the genotype o f the donor.
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Complete chimerism (CC) was documented in 12 patients (KIT-5, KIT-6, K IT-17, 
KIT-18, KIT-19, KIT-21, KIT-22, KIT-23, KIT-24, KIT-25, KIT-29, and KIT-32), 
and mixed chimerism (MC) in one patient (KIT-4). Rejection was shown in two p- 
TM patients (KIT-15, KIT-16), and in one CML patient (KIT-30) (Table 18). 
Chimerism was evaluated initially using the STR polymoqjhisms. PAH polymorphism 
was used for uninformative cases with STR polymorphism typing. In 22 recipient- 
donor pairs, THOl was informative in ten pairs (KIT-5, KIT-6, KIT-15, KIT-16, 
KIT-18, KIT-21, KIT-22, KIT-24, KIT-25, and KIT-32); F13A01 in five pairs, (KIT- 
15, KIT-16, KIT-21, KIT-23, and KIT-29); vWA in four pairs, (KIT-4, KIT-16, KIT- 
17, and KIT-21); and FES /FPS in three pairs (KIT-6, KIT-19, and KIT-21). PAH 
was analyzed in ten cases, and was informative in two of them (KIT-23, KIT-30) 
(Table 17). The chimerism status of 11 pairs (KIT-4, KIT-5, KIT-17, KIT-18, KIT- 
19, KIT-22, KIT-24, KIT-25, KIT-29, KIT-30, and KIT-32) were determined based 
on the information at one locus; three pairs (KIT-6, KIT-15, and KIT-23) at two loci; 
one pair (KIT-16) at three loci; and one pair (KIT-21) at four loci. For the remaining 
six recipient-donor pairs (KIT-1, KIT-10, KIT-11, KIT-12, KIT-13, and KIT-14) all 
five loci were non-informative (Table 18).
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Table 17 : Analyzed Polymorphic Loci for Chimerism Evaluation
Case PAH T H O l FES / FPS vWA F13A01 Results (+ days)
KIT-1 M I(+180)
KIT-4 - - - + - MC (+491)
KIT-5 - - CC (+153)
KIT-6 + + - - CC (+590)
K IT-10 - - - - - N1(+132)
O T-11 - - - - - NI(+187)
K IT-12 - - - - - N1(+1042)
K IT-13 - - - - - N I(+?)
KIT-14 - - - - N1(+367)
KIT-15 + - - + RJC (+270)
KIT-16 + - + + RJC (+605)
KIT-17 - - - + - CC (+75)
KIT-18 + - - - CC (+64)
KIT-19 - 4- - - CC (+39)
KIT-21 + + + + CC (+2920)
KIT-22 + - - - CC (+469)
KIT-23 + - - - + CC (+15)
KIT-24 + - - - CC (+45)
KIT-25 + - - - CC (+15)
KIT-29 - - - + CC (+118)
KIT-30 + - - - - RJC (+140)
KIT-32 + - - - CC (+44)
_____ ______ .... ........ .  — _ _ ---------------- ... . ............ ............... ................ ............. ............. - .......— ■
N1: Non-Informative
+: Informative
RJC : Rejection 
Not informative
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Table 18 : STR and PAH VNTR Analyses for Chimerism Evaluation
Case Disease
Time of
PCR
Analysis
(days)
Informative
Loci
Chimeric
Status
1. Krr-1 CML (Ph+) +54,+180 none Unknown
2. KIT-4 AMDL +456, +491, +140, +230 (2 BM T) VW A MC
3. KIT-5 A M L (M 6 ) + 5 0 ,+ 1 5 3 THO l CC
4. KlT-6 AMT. +590 T f iO l, FKS/FPS CC
5. KIT-IO AM L + 1 5 ,+ 1 3 2 none Unknown
6. K i r - l l AM L (M 6) +187 none Unknown
7. K IT-12 AM L + 1042 none Unknown
8. KIT-13 CML +? none Unknown
9. K IT-14 AM L (M 2) +367 none Unknown
10. KTT-15 p-TM + 6 0 ,+ 1 8 0 , +270 F 1 3 ,T H 0 1 Rejection
11. KTT-16 P-TM +395, +485, +605 VW A, T H O l, F13 Rejection
12. K lT-17 N fn . + 14, +60, +75 VWA CC
13. KIT-18 CML +38, +64 THO l CC
14. KTT-19 AM L +39 FES/FPS CC
15. KIT-21 AM L +2920 VW A,THO l,FES,F13 CC
16. KIT-22 AM L(M 3) +469 TOO l CC
17. KTT-23 M D S + AML +15 PAPI,F13 CC
18. KlT-24 AM L +45 THO l CC
19. K rr-25 .AML + 15 THOl CC
20 . KTT-29 CML + 118 F13 CC
2 1 . K rr-30 CML + 1 ,+ 2 3 ,+ 5 1 ,+ 1 4 0 PAH Rejection
2 2 . KIT-32 CML +2, +44 THOl CC
CML: Chronic myelogenous leukemia 
AML; Acute myelogenous leukemia 
MDS: Myelodysplastic syndromes 
NHL: Non Hodgkin’s lymphoma
P-TM; p-thalassemia 
MC : Mixed chimeric 
CC: Complete Chimeric 
+ : Number of days after-transplantation
95
1.1 Visualization of DNA Samples
Isolated DNA samples were run on 1.2 % agarose gels.
1 2 3 4 5 6 7
726 bp
Figure 11: Patient DNA Samples
Lane 1: <|)X 174 HinD, Lane 2: 97-325 (KIT 19), Lane 3: 97-326 (KIT 19) 
Lane 4: 97-348 (KIT 22), Lane 5: 97-381 (KIT 23), Lane 6: 97-555 (KIT 18) 
Lane 7: 97-558 (KIT-37)
1.2 Polymerase Chain Reaction
Isolated DNA samples were amplified by PCR with STR and PAH loci specific 
primers. STR amplification products were run on 2 % agarose gel before PAGE 
(Figure 12). PAH VNTR amplification products were run on 3 % agarose gel instead 
o f polyacrylamide gels as the polymorphism was 30 nucleotide repeats. (Figure 13). 
MetaPhor agarose gel electorphoresis enabled the separation o f STR alleles without 
application o f PAGE (Figure 14).
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Figure 12 : PCR Amplification of THOl and FES / FPS Loci
Lanes 2-6 are THOl amplifications (179-203 bp), and Lanes 7 and 8 are FES / FPS 
amplifications (222-250 bp).
L a n e  1: <|)X 174 Hinfl, L a n e  2: 97-35 (KIT 5), L a n e  3: 97-315 (KIT 5), L a n e  4: 97- 
500 (KIT 5), L a n e  5: 97-36 (KIT 5), L a n e  6: 97-563 (KIT 37), L a n e  7: 97-147 
(KIT 10), L a n e  8: 97-148 (KIT 10)
1 2 3 4 5 6 7 8
AB AB AB AB AB AC AC
Figure 13: PCR Amplification of PAH VNTR Locus for KIT-2 and KIT-23
Expected sizes could be 380 bp, 470 bp, 500 bp, 530 bp, 560 bp, or 650 bp according 
to the number o f copies o f the 30 nucleotide repeats. Lanes 2-5 represent samples o f 
KIT-2, and Lanes 6-8 represent samples o f KIT-23. + indicates number o f days in 
post transplantation period. Possible genotypes are indicated below the figure. While 
KIT-2 is non-informative, KIT-23 is complete chimeric for PAH VNTR locus.
L a n e  1: 100 bp DNA ladder. L a n e  2: 97-565 (pre). L a n e  3: 97-18 (+62), L a n e  4: 
97-566 (+203), L a n e  5: 97-20 (donor). L a n e  6: 97-381 (pre). L a n e  7: 97-494 (+15), 
L a n e  8: 97-403 (donor)
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1 2 3 4 5 6 7 8
200 bp 200 bp
AB AB AA AA AA AA
Figure 14: MetaPhor Agarose Gel Showing Complete Chimerism at vWA Locus 
for KIT-17
2% MetaPhor agarose gel was prepared for visualization o f amplification products. 
The expected size for vWA locus is 139-167 bp. Pre indicates the patient sample 
taken before the transplantation. Possible genotypes are indicated below the figure. 
Complete chimerism was demonstrated for K IT-17 at vWA locus.
Lane 1: <1)X 174 Hinfl, Lane 2: 97-320 (pre). Lane 3: 97-321 (pre). Lane 4: 97-380 
(+14), Lane 5: 97-488 (+60), Lane 6: 97-548 (+75), Lane 7: 97-549 (donor). Lane 
8: 100 bp DNA ladder
1.3 Polyacrylamide Gel Electrophoresis
After PCR products are checked on agarose test gels, they are run on 8-12 % 
denaturing polyacrylamide gels and the analysis is completed after silver staining. In 
the following figures, different outcomes are shown ; Rejection (Figure 15), complete 
chimeric (CC) (Figure 16, Figure 17), and non-informative (N1) (Figure 18).
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10 11 12 13 14 15
200 bp
100 bp
AB AB AB AB AC AC DE DE DE DE FE FE GG
Figure 15; Rejection Based on vWA and THOl Genotype in KIT-16
8 % polyacrylamide gel was prepared for visualization o f the amplified products. 
Lanes 2-7 indicate amplified samples for vWA locus and Lanes 8-13 indicate samples 
amplified for THOl locus. Lane 14 indicates a positive control sample for F13A01 
locus with known homozygous genotype, and Lane 15 indicates negative control. The 
expected sizes for vWA, TH O l, and F13A01 are 139-167 bp, 179-203 bp, and 283- 
331 bp respectively. Possible genotypes are indicated below the figure. Rejection was 
demonstrated for KIT-16 at vWA and THOl loci.
L a n e  1: 100 bp DNA ladder.
L a n e  2: 97-384 (pre). L a n e  3: 97-316 (+395), L a n e  4: 97-317 (+485), L a n e  5: 97- 
385 (+605), L a n e  6: 97-318 (donor). L a n e  7: 97-319 (donor), (vWA)
L a n e  8: 97-384 (pre). L a n e  9: 97-316 (+395), L a n e  10: 97-317 (+485), L a n e  11: 
97-385 (+605), L a n e  12: 97-318 (donor). L a n e  13: 97-319 (donor), (THOl)
L a n e  14: positive control sample (F13A01), L a n e  15: negative control
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AB AB AC AC AC
Figure 16: Complete Chimerism Based on FES / FPS Genotype in KIT-19
12 % polyacrylamide was prepared for visualization o f amplified fragments. Possible 
genotypes are indicated below the figure. Complete chimerism was demonstrated for 
K IT-19 at FES / FPS locus.
Lane 1: 97-324 (pre), Lane 2: 97-325 (pre). Lane 3: 97-509 (+39), Lane 4: 97-326 
(donor). Lane 5: 97-510 (donor)
AB BC BC
Figure 17: Complete Chimerism Based on THOl Genotype in KIT-25
12 % polyacrylamide was prepared for visualization o f amplified fragments. Possible 
genotypes are indicated below the figure. Complete chimerism was demonstrated for 
KIT-25 at THOl locus.
Lane 1: 97-407 (pre). Lane 2: 97-495 (+15), Lane 3: 97-509 (donor)
1 0 0
10 11 12 13
300 bp
AB AB AB CD CD CD EF EF EF GH GH GH
Figure 18:: Non-Informative Results at vWA, THOl, F13A01, and FES / FPS 
Loci in KIT-21
12 % polyacrylamide was prepared for visualization o f amplified fragments. Possible 
genotypes are indicated below the figure. Lanes 2-4 indicate samples for vWA 
amplified products. Lanes 5-7 for THOl amplified products. Lanes 8-10 for F13A01 
amplified products, and Lanes 11-13 for FES / FPS amplified products. KIT-21 was 
shown to be non-informative at all four loci analyzed. The expected sizes for vWA, 
TH O l, F13A01, and FES / FPS are 139-167 bp, 179-203 bp, 283-331 bp, and 222- 
250 bp respectively.
L a n e  1: 100 bp DNA ladder.
L a n e  2: 97-337 (pre). L a n e  3 : 97-335 (+2920), L a n e  4: 97-336 (donor), (vWA) 
L a n e  5: 91-221 (pre). L a n e  6: 97-335 (+2920), L a n e  7: 97-336 (donor), (THOl) 
L a n e  8: 97-337 (pre). L a n e  9: 97-335 (+2920), L a n e  10: 97-336 (donor), (F13A01) 
L a n e  11: 97-337 (pre). L a n e  12: 97-335 (+2920), L a n e  13: 97-336 (donor) (FES / 
FPS)
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In this part o f the study, the fusion transcripts that are generated by the chromosomal 
rearrangements were detected by RT-PCR analysis. For this purpose, RNA was 
isolated from the peripheral blood and bone marrow samples of patients with different 
hematological malignancies. Then first strand cDNA was synthesized which was 
further amplified with translocation and inversion specific primers. The analysis was 
carried out according to the panel prepared (Table 15). There are five translocations 
and one inversion type rearrangement in the panel. A total of 49 samples which 
belong to 44 patients were analyzed. Nine o f these patients underwent allogeneic 
transplantation. RT-PCR positivity for these patients indicates minimal residual 
disease. 17 patients are newly diagnosed for which RT-PCR positivity indicates the 
presence o f the fusion transcripts that are characteristic for the malignancy involved.
2. Detection of Fusion Transcripts by RT-PCR Analysis
Among 14 AML patients only one (FS-23) was shown to be positive for t (15;17). 
Four patients (FS-2, FS-8, FS-21, and FS-29) are positive for inv 16. Altered size 
fragments were observed in two patients (FS-8, FS-29) as 2"“* PCR products. These 
may represent different breakpoints in chromosome 16. Our single ALL patient (FS- 
3) is negative for all the translocations analyzed (9;22, 4;11, and 1;19). Among three 
MDS patients only two of them (FS-5, and FS-6) are positive for t (9;22) while the 
third one (FS-12) is negative for all o f the six rearrangements analyzed (Table 19). It 
is interesting to note that among the nine translocation positive acute leukemia 
patients, seven o f them (FS-8, FS-11, FS-14, FS-23, FS-26, FS-29, and FS-46) are
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newly diagnosed (see also Table 10). This point stresses the importance of performing 
a fusion transcript detection test for the diagnosis o f hematological malignancies.
Translocation 9;22 analysis was performed in a total o f 26 CML patients. 14 o f them 
are translocation positive while in 12 o f them no fusion transcript was detected. 
Among the translocation positive patients, seven o f them (FS-13, FS-17, FS-20,, FS- 
30, FS-31, FS-35 and FS-43) are positive only for the 198 bp transcript, while three 
patients (FS-10, FS-24, and FS-42) are positive only for the 273 bp transcript. Four 
patients (FS-4, FS-16, FS-33, and FS-45) are shown to be positive for both o f the t 
(9;22) transcripts (Table 20). Among the 14 translocation positive CML patients, 
eight o f them (FS-10, FS-16, FS-27, FS-31, FS-33, FS-35, FS-38, and FS-45) are 
newly diagnosed (see also Table 10). All three patients that are under interferon 
treatment (FS-17, FS-20, FS-43) are positive for the 198 bp transcript. All seven 
patients (FS-22, FS-25, FS-28, FS-32, FS-34, FS-39, and FS-44) who underwent 
allogeneic PBSCT are negative for t (9;22) transcripts which is an indication o f MRD 
negativity (Table 20).
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Table 19 : RT-PCR Analysis for Detection of Fusion Transcripts in Acute
Leukem ia Patients
Patient Clinical
Code Diagnosis t (9;22) * 1t ( 15;17) t (8 ;21) inv 16 t (4 ;11) t ( 1;19) Result
1. FS-18 AML _ . NA NA TND
2. FS-47 AML - - - - NA NA TND
3. FS-8 AML-Ml - - - + NA NA inv 16 +
4. FS-29 AML-Ml - - 4- NA NA inv 16 +
5. FS-46 AML-Ml - - - - NA NA TND
6. FS-7 AML-M2 - - - - NA NA TND
7. FS-15 AML-M2 - - - - NA NA TND
8. FS-1 AML-Eo M3 NA NA NA - NA NA TND
9. FS-26 AML-M3 - - - NA NA TND
lO.FS-2 AML-M4 - - - 4- NA NA inv 16 +
ll.FS-11 AML-M4 - - - - NA NA TND
12.FS-21 AML-Eo M4 - - - 4- NA NA inv 16 +
13.FS-23 AML-M4 - + - - NA NA t(15;17) +
14.FS-14 AMLbiphenotypic - - - - NA NA TND
15.FS-3 ALL - NA NA NA - - TND
16.FS-5 MDS-RAEBt +  /  + - - - - - t (9 ;2 2 ) +
17.FS-6 MDS-RAEB +  / - - - - - - t (9 ;2 2 ) +
18.FS-12 MDS - - - - - - TND
TND: Translocation not detected
NA: Analysis not applicable (Table 15)
* First +  denotes for the positivity for 198 bp product and second +  denotes positivity
for 273 bp product in t (9;22).
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Table 20 : RT-PCR Analysis for Detection of Fusion Transcripts in Chronic 
Myelogenous Leukemia (CML) Patients
Patient Code t (9;22) Result
i. FS-4 + /+ 198 bp + 273 bp +
2. FS-9 translocation negative
3. FS-10 - /  + 273 bp +
4. FS-13 + / - 198 bp +
5. FS-16 + /+ 198 bp + 273 bp +
6. FS-17 + / - 198 bp +
7. FS-20 + / - 198 bp +
8. FS-22 - / - translocation negative
9. FS-24 - /  + 273 bp +
lO.FS-25 translocation negative
ll.FS-27 translocation negative
12.FS-28 translocation negative
13.FS-30 + / - 198 bp +
14.FS-31 + / - 198 bp +
15.FS-32 - / - translocation negative
16.FS-33 + /+ 198 bp +, 273 bp +
17.FS-34 - / - translocation negative
18.FS-35 + / - 198 bp +
19.FS-36 translocation negative
20.FS-38 translocation negative
21.FS-39 translocation negative
22.FS-40 translocation negative
23.FS-42 - /  + 273 bp +
24.FS-43 + / - 198 bp +
25.FS-44 translocation negative
26.FS-45 + /+ 198 bp +, 273 bp +
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2.1 Visualization of RNA Samples
The isolated RNA samples were run on 1.2 % formaldehyde-containing agarose gels 
which were stained with ethidium bromide and destained in ddH20  before they were 
photographed.
1 2 3 4 5 6 7 8 9 10 n  12
5000 bp 
3000 bp
28s (4800 bp) 
18s (1900 bp)
Figure 19: Patient RNA Samples
Lane 1: 1 kb DNA ladder. Lane 2: 98-53 (FS-13), Lane 3: 98-54 (FS-14), Lane 4: 
98-55 (FS-15), Lane 5: 98-56 (FS-15), Lane 6: 98-57 (FS-16), Lane 7: 98-58 (FS- 
17), Lane 8: 98-61 (FS-18), Lane 9: 98-62 (FS-19), Lane 10: 98-63 (FS-20), Lane 
11: 1 kb DNA ladder
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2.2 cDNA Synthesis
The integrity o f the synthesized cDNA samples was checked by the amplification o f 
the P-actin locus by RT-PCR. The amplified fragment is 551 bp using primer pair TC- 
66 and TC-67 (Table 12). As depicted in Figures 20 A and 20 B cDNA synthesis o f 
all the samples were successfiilly achieved and amplification was observed.
1 2 3 4 5 6 7 8 9 10 11 12
600 bp 
500 bp
553 bp
Figure 20 A : p-Actin Amplification of cDNA Samples
Lane 1: 100 bp DNA ladder. Lane 2: 97-664 (FS-1), Lane 3: 98-28 (FS-2), Lane 4: 
98-29 (FS-3), Lane 5: 98-30 (FS-4), Lane 6: 98-31 (FS-4), Lane 7: 98-35 (FS-6), 
Lane 8: 98-36 (FS-7), Lane 9: 98-37 (FS-8), Lane 10: 98-45 (FS-9), Lane 11: 98- 
47 (FS-10), Lane 12: 174 Hinfl
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1 2 3 4 5 6 7 8 9 10 11 12
600 bp 
500 bp
553 bp
Figure 20 B : P -A c tin  Amplification of cDNA Samples
L a n e  1: 100 bp DNA ladder. L a n e  2: 98-48 (FS-11), L a n e  3: 98-52 (FS-12), L a n e  
4: 98-53 (FS-13), L a n e  5: 98-54 (FS-14), L a n e  6: 98-55 (FS-15), L a n e  7: 98-56 
(FS-15), L a n e  8: 98-57 (FS-16), L a n e  9: 98-63 (FS-20), L a n e  10: HT29 
translocation negative cell line, L a n e  11: negative control L a n e  12: <t>X 174 Hinfl
2.3 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
For each o f the chromosomal rearrangements analyzed, primer pairs, expected sizes 
are depicted in the schematic presentations and the corresponding results obtained are 
given in the following sections:
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For the PCR reaction, GA-114 / GA 111 pair was used together with the 
p-actin control primers. In the second step, this reaction mixture was used 
as the template and primed with inner primers which is GA-113 / GA-112 
pair. Location o f the oligomers is indicated in Figure 21 below. Due to the 
alternative splicing o f BCR gene, two different fusion transcripts are 
generated as 198 bp and 273 bp respectively. As an additional internal 
control, GA-431 / GA-111 pair was also used and 202 bp fragment was 
successfully amplified (data not shown).
2.3.1 t (9;22) (q34;qll)
Chr.9 
bcr exons
Chr.22 
abl exons
b1 b2 b3 a2 a3
GA 114 — GA 431 —► i<— GA111 Iststep
GA 113
abl control =202 bp 
GA 112
2nd ^ep
b2a2=198 bp b3a2= 273 bp
Figure 21: Schematic Representation of the Amplified Region for t (9;22)
(Adapted from Frenoy et al., 1994)
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553 bp
200 bp
fi-actin control
198 bp transcript
Figure 22 A: RT-PCR Amplification for t (9;22) q34;qll)
Lanes 2, 4, and 6 indicate 1® PCR reactions while Lanes 3, 5, and 7 indicate 2"** PCR
reactions o f the corresponding samples. Lane 8 is the negative control o f the 2”‘‘ PCR 
reaction. Sample 98-58 (FS-17) was observed to be positive for the 198 bp b2a2 
fusion transcript while other samples, 98-61 (FS-18) and 98-64 (FS-21), were 
negative for both o f the transcripts.
Lane 1: (|)X 174 Hinfl, Lane 2: 98-58 (1“), Lane 3: 98-58 (2"'’) (FS-17), Lane 4:
98-61 (1^), Lane 5: 98-61 (2"**) (FS-18), Lane 6: 98-64 (1“), Lane 7: 98-64 (2"“)nd\
(FS-21), Lane 8: negative control (2"'*)
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Figure 22 B: RT-PCR Amplification for t (9;22) (q34;qll)
Lanes 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20 indicate 1*^  PCR reactions while Lanes 3, 
5, 7, 9, 11, 13, 15, 17, 19 and 21 indicate 2'“' PCR reactions o f the corresponding 
samples. Samples 98-85 (FS-30), 98-86 (FS-31), and 98-90 (FS-35) were observed to 
be positive for the 198 bp b2a2 fusion transcript while other samples, 98-72 (FS-26), 
98-79 (FS-27), 98-80 (FS-28), 98-84 (FS-29), 98-87 (FS-32), and 98-89 (FS-34) 
were negative for both o f the transcripts. Sample 98-88 (FS-33) was observed to be 
positive for both b2a2 (198 bp), and the b3a2 (273 bp) fusion transcripts.
Lane 1:100 bp DNA ladder.
Lane 2: 98-72 (1^), Lane 3: 98-72 (2"‘*) (FS-26), 
Lane 4: 98-79 (1^), Lane 5: 98-79 ^  (FS-27), 
Lane 6: 98-80 (1^), Lane 7: 98-80 (2"‘‘) (FS-28), 
Lane 8: 98-84 (1^), Lane 9: 98-84 ¿ ”‘‘) (FS-29), 
Lane 10: 98-85 (1^), Lane 11: 98-85 (2'“’) (FS-30), 
Lane 12: 98-86 (1^), Lane 13: 98-86 (2"**) (FS-31), 
Lane 14: 98-87 (1^), Lane IS: 98-87 ¿ " ‘*) (FS-32), 
Lane 16: 98-88 (1“^), Lane 17: 98-88 (2"**) (FS-33), 
Lane 18: 98-89 (l^X Lane 19: 98-89 ¿*“*) (FS-34), 
Lane 20: 98-90 (1^), Lane 21: 98-90 (2”**) (FS-35), 
Lane 2 2 :^ ^  174 Hinfl
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Figure 22 B: RT-PCR Amplification for t (9;22) (q34;qll)
Lanes 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20 indicate 1®* PCR reactions while Lanes 3, 
5, 7, 9, 11, 13, 15, 17, 19 and 21 indicate 2"** PCR reactions o f the corresponding 
samples. Samples 98-85 (FS-30), 98-86 (FS-31), and 98-90 (FS-35) were observed to 
be positive for the 198 bp b2a2 fusion transcript while other samples, 98-72 (FS-26), 
98-79 (FS-27), 98-80 (FS-28), 98-84 (FS-29), 98-87 (FS-32), and 98-89 (FS-34) 
were negative for both o f the transcripts. Sample 98-88 (FS-33) was observed to be 
positive for both b2a2 (198 bp), and the b3a2 (273 bp) fusion transcripts.
Lane i.’lOO bp DNA ladder.
Lane 2: 98-72 (1^), Lane 3: 98-72 (2"·*) (FS-26), 
Lane 4: 98-79 (1*^ ), Lane 5; 98-79 (2"‘‘) (FS-27X 
Lane 6: 98-80 (1^), Lane 7: 98-80 ¿ " ‘*) (FS-28), 
Lane 8: 98-84 (1^), Lane 9: 98-84 (2"*') (FS-29), 
Lane 10: 98-85 (1^), Lane 11: 98-85 (2·“*) (FS-30), 
Lane 12: 98-86 (1^), Lane 13: 98-86 (2"**) ^S-31X  
Lane 14: 98-87 (1^), Lane 15: 98-87 ¿ " ‘‘) (FS-32), 
Lane 16: 98-88 (1^), Lane 17: 98-88 (2"“) (FS-33), 
Lane 18: 98-89 (1*"), Lane 19: 98-89 (2"‘‘) (FS-34), 
Lane 20: 98-90 (1“"), Lane 21: 98-90 (2'“') (FS-35), 
Lane 22: 174 Hinfl
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For the r ‘ PCR reaction, GA-136 / GA 137 pair was used together with the 
P-actiii control primers. In the second step, this reaction mixture was used 
as the template and primed with inner primers which is GA-138 / GA-139 
pair. Figure 23 is the schematic diagram o f the t (8;21) specific AML-1 / 
ETC fusion transcript, the location o f the primers used for the RT-PCR 
analysis and the size o f the PCR products generated. The sequence o f the 
primers are given in Table 12.
2.3.2 t (8;21) (q22;q22)
tel
Chrom osom e 21 
A M L 1
Chrom osom e 8 
E T C
■ . I , : , i . j !, I
G A  136 338 bp G A  137
cen
G A 1 3 8
185 bp
G A  139
Figure 23; Schematic Representation of the Amplified Region for t (8;21)
(Adapted from Downing ei a l ,  1993)
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Figure 24 : RT-PCR Amplification for t (8;21) (q22;q22)
Lanes 2, and 4 indicate 1®* PCR reactions while Lanes 3, and 5 indicate 2"** PCR 
reactions o f the corresponding samples. Although PCR is successful, both o f the 
samples, 98-123, and 98-124 are negative for the expected 185 bp fusion transcript 
(Lane3, Lane 5). Lane 6, and Lane 7 are negative controls o f 1“* and 2”** PCR 
reactions respectively.
Lane 1:100 bp DNA ladder. Lane 2: 98-123 (1“), Lane 3: 98-123 (2"‘‘) (FS-46)
Lane 4: 98-124 (1®*), Lane 5: 98-124 (2"“*) (FS-47), Lane 6: negative control (1“),
Lane 7: negative control (2"'*), Lane 8: (|)X 174 Hinfl
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For the PCR reaction, GA-119 / GA 121 pair was used together with the 
f^actin control primers. In the second step, this reaction mixture was used 
as the template and primed with inner primers which is GA-120 / GA-122 
pair. Figure 25 is the schematic diagram o f the t (15;17) specific MYL / 
RAR-a fusion transcript, the location o f the primers used for the RT-PCR 
analysis and the size o f the PCR products generated. The sequence o f the 
primers are given in Table 12.
2.3.3 t(15;17)(q22;q21)
M YL (15q22) RAR-a!pha (17q21)
5’
GA 119 GA 120 GA 122 GA 121
326 bp
435 bp
Figure 25: Schem atic Representation of the Amplified Region for t (15;17)
(Adapted from Biondi et al., 1992)
3’
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553 bp 
413 bp
''  ^rI%o.V^'^  '!’ 'Vv:vS'f^ .>;
. V. -
i
■326 bp
Figure 26: RT-PCR AmpUrication for t (15; 17) (q22;q21)
Lanes 2, 4, and 6 indicate PCR reactions while Lanes 3, 5, and 7 indicate 2"‘‘ PCR 
reactions o f the corresponding samples. Sample 98-67 (FS-23) was observed to be 
positive for the 326 bp fusion transcript (see also Table 19) while the other sample, 
98-56 (FS-23), was negative for the fusion transcript. PCR did not work for the 
sample 98-55 (FS-15) (Lanes 2, and 3).
Lane 1: 174 Hinfl, Lane 2: 98-55 (1*^ ), Lane 3: 98-55 (2"**) (FS-15), Lane 4:
98-56 (1^), Lane 5: 98-56 (2"") (FS-15), Lane 6: 98-67 ( r ) .  Lane 7: 98-67 (2"**) 
(FS-23), Lane 8:100 bp DNA ladder
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For the PCR reaction, GA-134 / GA 135 pair was used together with the 
(i-actin control primers. In the second step, this reaction mixture was used 
as the template and primed with inner primers which is GA-132 / GA-135 
pair. For an additional ALL-1 gene internal control, GA-132 / GA-133 pair 
was also used. Figure 27 is the schematic diagram o f the t (4; 11) specific 
ALL-1 / AF-4 fusion transcripts. The location o f the primers used for the 
RT-PCR analysis and the size o f all possible PCR products generated 
according to breakpoint positions and alternative splicing on ALL-1 and 
AF-4 genes are also depicted.
2.3 .4t(4;ll)(q21;q23)
Chr. 11 
ALL-1 exons
Chr. 4 
AF-4 exons
Ex5 Ex6 Ex7 Ex8 A B C
GA 134 GA 132 GA 133 GA 135
lei: ! A je C i
A B c
 ¡A1=286bp
Al! Posable RT-PCR Products
WEE B B1=245bp
i | j  b ] c j B2= 377bp
¿4, A B C A3= 5321 C B3=491bp i;!S
■===
|W ] C1=157bp
W: 7 IC C2= 289 bp
""s : 7 W· j c  I C3= 403bp
Figure 27: Schematic Representation of the Amplified Region for t (4; 11)
(Adapted from Cimino et al., 1996)
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553 bp
3-actin
Figure 28 : RT-PCR Amplification for t (4; 11) (q21;q23)
Lanes 2, and 4 indicate 1  ^ PCR reactions while Lanes 3, and 5 indicate 2"** PCR 
reactions o f the corresponding samples. Both o f the samples, 98-29 (FS-3) and 98-34 
(FS-5) were negative for t (4; 11) specific transcripts even though P-actin was 
successfully amplified.
Lane 1: <|)X 174 H infl, Lane 2: 98-29 (1^), Lane 3: 98-29 (2"**) (FS-3), Lane 4: 98- 
34 (1**), Lane 5: 98-34 (2"*') (FS-5), Lane 6: 100 bp DNA ladder
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Pj2A / PBX-I fusion transcript is amplified with primers GA-129 and GA-130 and a 
164 bp transcript is obtained. A 180 bp fragment o f the normal E2A transcript is also 
amplified as a control for RNA integrity, in addition to the P-actin amplification, 
using the primers GA-129 and GA-131. Figure 29 is a schematic representation of 
PCR products obtained together with the primers used for RT-PCR analysis.
2.3.5 t ( l ;  19) (q23;p23)
5’
5’
E2A ( Chr 19p13)
GA 1291
E2A ( chr 19p13)
G A 129·
164 bp
180 bp
PBX1 ( Chr 1p13)
GA 130
3’
3’
GA131
Figure 29: Schematic Representation of the Amplified Region for t (1;19)
(Adapted from Privitera et ciL, 1992)
1 1 8
1 2 3 4 5 6 7 8
553 bp
200 bp 
151 bp
p-actin control
E2A control
Figure 30: RT-PCR Amplification for t (1;19) (q23;p23)
For samples 98-29 (FS-3) (Lane 2), 98-35 (FS-6) (Lane 3), and Focus cell line 
(translocation negative) (Lane 6), PCR did not work. For 98-48 (FS-11) (Lane 4), 
and 98-52 (FS-12) (Lane 5), control reaction products were present but no t (1;19) 
specific fusion transcripts could be detected.
Lane 1: <|)X 174 Hinfl, Lane 2: 98-29 (FS-3), Lane 3: 98-35 (FS-6), Lane 4: 98-48 
(FS-11), Lane 5: 98-52 (FS-12), Lane 6: Focus cell line. Lane 7: negative control. 
Lane 8: 100 bp DNA ladder Lane 2: 98-29 (FS-3)
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2.3.6 inv 16 (pl3;q22)
For the 1  ^PCR reaction, GA-128 / GA 125 pair was used together with the 
P-actin control primers In the second step, this reaction mixture was used 
as the template and primed with inner primers which is GA-126 / GA-127 
pair. The most common outcome is a 414 bp 1®^ PCR product and 221 bp 
2nd product. Figure 31 is the schematic diagram of the inv 16 specific 
CBFB /  M YH ll fusion transcripts (A, B, C, D). The location o f the primers 
used for the RT-PCR analysis and the size of all possible PCR products 
generated are also depicted.
B
A,B
A.B
1 3
1921
1 3
2M
GA 128,125:4^4bp (1,2M) 
GA 124,125: 604 bp (A,2M)
1528-. -. ■ -. -i-r-. ^  · · ' ■ · - · M  ^- ·: * -  ^· · · ·: · 1»,», 1, * j 1,», i, 1, 1, 1,11», 1, ',», * j 1,»,»,», 1, », 1,», 1------------------------------
■ . · · V V · i ■ : . ·>■·  · ■ A_ · · . · . · , ♦ . l i l t  * i S  * t S  S* d  1
.......... 2ivi
1 3
1201
GA 126,127:224 bp
(1,2M)
GA 128,125: 1134 bp G/\ 126,127: 548 bp
..;
1 3
994
2M
GA 124,125: 1404bp 
(A,2M)
(CBFB)
(1,2M) 2  ^ (3,4)
GA 128,125:1341 bp GA 126,12T. 755 bp
Figure 31: Schematic R epresentation of the Amplified Region for inv 16
(Adapted from Claxton et a l, 1994)
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Alternative
transcript 551 bp 
/3-actin 
control
Figure 32: RT- PCR Amplification for inv 16 (pl3;q22)
Lanes 2, 4, and 6 indicate 1  ^PCR reactions while Lanes 3, 5, and 7 indicate 2"‘‘ PCR 
reactions o f the corresponding samples. Sample 98-84 (FS-29) was observed to have 
a strong band at around 800 bp level which is unique to 2"** PCR (Lane 3). This might 
be an indication o f an alternatively spliced transcript. For the other samples 98-123, 
and 98-124 the inv 16 fusion transcripts were not detected (Lanes 5, and 7 
respectively), p-actin control was successfully amplified (Lanes 2, 4, and 6).
Lane 1: <(>X 174 H infl, Lane 2: 98-84 (1% Lane 3: 98-84 (2"‘‘) (FS-29), Lane 4: 
98-123 (1“^), Lane 5: 98-123 (2"**) (FS-46), Lane 6: 98-124 (L ‘), Lane 7: 98-124 
(2nd) Lane 8: 100 bp DNA ladder
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IV. DISCUSSION
In this study, we have introduced molecular diagnostic tests for hematological 
malignancies. These tests include DNA based chimerism evaluation in bone marrow 
or peripheral blood stem cell transplantation patients; and RNA based fusion 
transcript detection in various hematological malignancies. The DNA based tests 
relied on the analysis o f four STR (vWA, TH O l, F13A01, and HUMFES / FPS) and 
one VNTR (PAH) polymorphisms. The RNA based tests targeted six frequently seen 
chromosomal rearrangements associated with hematological malignancies. These are t 
(9;22), t (15;17), t (8;21), t (4;11), t (1;19), and inv 16. To the best of our knowledge, 
this study presents the first molecular genetic data on hematological malignancies 
associated chromosomal rearrangements in the Turkish population with the exception 
o f t (9;22) which was done previously (Eren et al., 1996).
The first part of this study involves the evaluation of chimerism status in patients who 
underwent allogeneic transplantation. Due to the fact that the degree of chimerism 
achieved after transplantation has strong influence on the outcome of transplantation, 
in development of GVHD, in failure or graft rejection, or in relapse o f disease; 
chimerism evaluation is o f great importance. Chimerism status is influenced by a 
number o f factors such as gender, incidence of GVHD, disease type, conditioning 
regimen, and HLA compatibility. Detection of complete chimerism (CC) is a good 
prognostic factor in patients who underwent transplantation. On the other hand,
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mixed chimerism has been correlated with leukemic relapse therefore, detection o f 
mixed chimerism is useful in monitoring patients susceptible to leukemic relapse.
PCR-based analysis o f DNA polymorphisms is a very sensitive technique and the 
sensitivity is further increased by the use o f highly polymorphic loci. Therefore an 
important factor in the DNA polymorphism based chimerism analysis is the choice o f 
polymorphic loci. One VNTR and four STR loci were analyzed in 22 recipient-donor 
pairs. Twelve patients (54.5 %) were complete chimeric, and one patient was mixed 
chimeric. A total o f six cases were non- informative for all the loci analyzed. There 
were three rejection cases two of which had ß-thalassemia and one had CML. It is 
known that if relapse is demonstrated for CML patients, IFN -a is a therapy o f choice 
when another transplantation is not available. This patient has been demonstrated to 
have rejection at a relatively early post-transplantation period (+140) (Table 17, KIT- 
30). Therefore, alternative therapy options may well be considered. For the non- 
informative cases, definitely, different polymorphic loci should be included for the 
analysis.
Molecular monitoring of transplantation patients is invaluable in the early detection 
and confirmation o f relapse. We have experienced this fact in one of our acute 
myelogenous leukemia patients. KIT-4 is an AML-M4 patient who was in 
hematologic complete remission when she was reported to be complete chimeric 
based on our molecular analysis as well. The analysis was performed with all four 
STR loci at first and she was found to be informative at vWA locus with which
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further analyses were carried out. After a few months she relapsed with a different 
type o f leukemia, namely plasma cell leukemia. STR analysis o f her peripheral blood 
sample and bone marrow aspirate revealed mixed chimerism confirming the relapse at 
molecular level. Then the patient was in second complete remission by the 
chemotherapy and DLI (donor lymphocyte infusion) and complete chimerism was 
shown for the second time by the examination of peripheral blood cells and bone 
marrow. Five months later, she had a second relapse with blastic cells in CSF 
(cerebrospinal fluid). STR analysis was performed by examining both the peripheral 
blood cells and also CSF o f the patient. The peripheral blood smear and bone marrow 
aspirate revealed that she was still in second complete remission and genotype results 
were compatible with complete chimerism. However, although CC was the case in 
peripheral blood cells, STR analysis o f CSF showed mixed chimerism which was 
consistent with the CNS (central nervous system) confined relapse. This case was 
important in two aspects. The first one is that, repetitive chimerism analyses is o f vital 
importance for close monitoring of the disease and the for the detection of the time o f 
relapse. The second one is that, PCR-based chimerism evaluation is sensitive enough 
to confirm the clinical and hematological situation o f patients with such malignancies. 
It is known that isolated CNS relapse occurs rarely in patients treated with bone 
marrow transplantation and the finding that the patient was complete chimeric in her 
peripheral blood cells but mixed chimeric in her CSF was consistent with the clinical 
findings of CNS relapse without systemic relapse.
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Among the 22 recipient-donor pairs studied, THOl was informative in ten of 22 (45.5 
%) pairs, F13A01 in five o f 22 (22.7 %), vWA in four of 22 pairs (18.2 %), and FES / 
FPS in three o f 22 pairs (13.6 %). In ten pairs PAH VNTR was also analyzed and was 
found to be informative in two of 10 (20 %) pairs. Six o f these ten pairs were the ones 
that were non-informative with the four STR loci. They were still non-informative 
after PAH VNTR analysis was also included (Table 17).
Regarding the time o f PCR analysis, complete chimerism could be detected 15 days 
post-transplantation as the earliest, and 2920 days (about 8 years) post-transplantation 
as the latest which is quite significant. The latest duration is an indicative o f how long 
the complete chimerism status is maintained and thus is a good prognostic factor. 
These repetitive analyses not only enables the detection o f the time o f relapse but also 
provides the physician with the information on whether to repeat the transplantation 
procedure or continue with alternative follow-up approaches.
In conclusion, PCR-based detection of DNA polymorphisms appears to be a sensitive 
and powerful technique for the evaluation o f chimerism status in patients treated with 
allogeneic transplantation. The availability of different polymorphic marker will 
increase the sensitivity of the analysis. The evaluation of the prognostic value and 
clinical significance o f the DNA polymorphism results require further analysis o f more 
patients for longer periods. A final remark is that this system is established and is 
applicable for prognostic analyses.
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The second part o f this study focused on the detection o f fusion transcripts that are 
generated by chromosomal rearrangements in various acute and chronic leukemias. 
This approach has both diagnostic and prognostic implications depending on whether 
the patient has undergone any kind of treatment or not. It is diagnostically important 
because, certain chromosomal rearrangements are closely associated with certain 
types and even subtypes o f hematological malignancies. In this respect, the detection 
o f fusion transcripts not only adds accuracy to the diagnosis brought by the 
conventional means but also provides insight into the pathogenesis o f the malignancy 
under question. This approach has also prognostic importance because it provides the 
detection o f minimal residual disease for the patients who have undergone allogeneic 
transplantation. MRD is an indicator for a prediction o f relapse. MRD negativity at 
the termination o f therapy, which could be demonstrated by the RT-PCR based 
analyses, suggests long term DFS (disease free survival). Therefore, more precise 
evaluation o f MRD is necessary with regard to therapeutic strategy in monitoring of 
the disease. RT-PCR based analysis of the chromosomal breakpoints and the 
detection o f fusion transcripts is a very sensitive and powerful approach for this 
evaluation.
Due to the importance of such an evaluation, special precautions are needed to avoid 
false positive results due to contaminants and false negative results due to insufficient 
yields. To avoid false positives, two kinds o f negative controls, a normal translocation 
negative RNA sample, and a blank sample containing all the required reagents except 
for RNA, were used. For the normal RNA sample, translocation negative
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hepatocellular carcinoma cell lines (Focus, WRL, HT29) were used. cDNA samples 
synthesized from the RNA obtained from those cell lines were amplified with 
translocation specific primers and no amplification was observed with any o f the 
rearrangements analyzed in the panel (Table 15). To eliminate false negatives resulting 
from RNA degradation, poor reverse transcription or inadequate PCR amplification, 
cDNA fragments spanning the ¡5-actin gene and / or one o f the genes that are 
disrupted due to translocations (c-ABL in t(9;22) Figure 21, ALL-1 in t(4 ; ll)  Figure 
27, and E2A in t(l;19) Figure 29) were coamplified together with the translocation 
specific fusion transcripts. The absence o f /3-actin, c-ABL, ALL-1 or E2A cDNAs 
would indicate false negativity. These precautions were kept throughout the analyses.
The translocation t (9;22) (q34;qll), which is typical for CML (95 %), but is also 
seen in AML and ALL, generates two kinds of fusion transcripts (198 bp, and 273 bp) 
depending on the actual breakpoint in BCR. 198 bp transcript is the product when the 
breakpoint is in the first intron. This analysis could help in diagnosis to -discriminate 
between a lymphoid blast crisis o f CML and de novo Ph+ bcr- ALL for the patients 
who are newly diagnosed. This discrimination is difficult because both leukemic states 
are clinically similar with extremely poor prognosis and the similar blast morphology 
of leukemic cells (Hermans et al., 1987)
This rearrangement was analyzed in CML (n=26), AML (n=13), MDS (n=3), and 
ALL (n= l) patients. Among the CML cases eight (FS-10, FS-16, FS-27, FS-31, FS- 
33, FS-35, FS-38, and FS-45) were newly diagnosed and did not have any treatment.
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Except FS-27 and FS-38, the other five patients are translocation positive (Table 20). 
Three o f the patients (FS-17, FS-20 and FS-43) were under interferon treatment and 
were shown to have the 198 bp transcript. Eight patients have been reported to 
undergo allogeneic BMT between the years 1992-1998. When the results are 
examined, it is seen that all o f these eight patients were negative for both o f the 
t(9;22) transcript at the time o f RT-PCR analysis. This supports that BMT is the 
treatment o f choice for CML patients. In none o f the analyzed AML, ALL and MDS 
patients t (9;22) transcripts were observed. This was not unusual because o f the 
strong association between CML and the presence o f Ph chromosome.
The translocation t (8;21) (q22;q22) is seen in 20 % o f AML-M2 cases and is 
associated with good prognosis. This rearrangement is analyzed in 13 AML cases 
with various subtypes (Table 19). The subtypes o f two patients (FS-18, FS-47) are 
unknown and one patient (FS-14) has biphenotypic AML. The analysis was also done 
for three MDS patients (FS-5, FS-6, FS-12) as well. All of these patients were 
negative for t (8;21) fusion transcript.
The t (15; 17) (q22; q21) is unique to AML-M3 (70-100 %) with intermediate 
prognosis. The detection o f PML / RAR-a transcript has important implications not 
only for assessing the MRD status, but also for management of patients with APL. It 
is a useful marker for AJPL diagnosis to identify patients who can benefit fi-om retinoic 
acid treatment. In this context, this rearrangement was analyzed in 13 AML and three 
MDS patients. The single positive result belongs to one AML-M4 patient (FS-23).
128
The inv 16 (pl3;q22) rearrangement is observed in 25 % of AML-M4 cases with 
good prognosis. The analysis was performed on 14 AML patients and three MDS 
patients. Altered size fragments were observed for two cases (FS-8, FS-29).These 
findings suggest that altered size fragments are alternative splicing products. 
Sequencing o f the 2’“^ PCR products o f these samples would be suggested to 
determine the actual breakpoints in the differentially spliced M YH ll gene. Another 
important observation was that, the expected 221 bp product was observed in two 
patients with M4 subtype (FS-2, and FS-21). FS-2 has been reported to have relapse 
which is consistent with the presence o f MRD.
The rearrangements t(4 ;ll)  (q21;q23) and t(l;19) (q23;p23) are observed in 100 % 
lymphoblastic ALL and 20-25 % pre-B cell ALL. In this study, these rearrangements 
are analyzed in three MDS and one ALL cases. However, in none of them the related 
transcripts could be observed. This is most probably due to the small size of the 
sample group. All necessary precautions were taken to avoid false negatives.
We have successfully demonstrated the presence o f t (9;22), t (15; 17), and inv 16 in 
our patient population. A more comprehensive study including cytogenetic analysis, 
and sequencing is needed together with fusion transcript detection to further 
characterize the altered size transcripts observed particularly in inv 16. They most 
probably represent alternative chromosomal breakpoints. In addition, all the results 
that have been reported as positive might be confirmed with Southern blot analysis 
using the fusion region specific probes for the hybridization.
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In conclusion, the importance o f molecular analyses in hematological malignancies 
comes from the fact that, they serve not only to detect but also to prevent, treat and 
reinduce remission in patients that relapsed after the allogeneic transplantation. These 
analyses should be performed widespread with a collaborative and comprehensive 
understanding to help patients with hematological malignancies.
130
V. REFEREN CES
Aronheim A., Shiran R., Rosen A., and Walker M. D. (1993) Cell-specific expression 
o f helix-loop-helix transcription factors encoded by the E2A gene. Nucleic 
Acids Res. 21 (7) : 1601-1606
Ausubel F. M., Brent R., Kigston R. E., Moore D. D., Seidman J. G., Smith J. A., and 
Struhl K. (1991) Current Protocols in Molecular Biology. 1, 2
Bajcetic M., Zigon N., Samardzic R., and Beleşlin D. B. (1998) Med Preg L. 51 (3- 
4): 135-139
Biondi A., Rambaldi A., Pandolfi P. P., Rossi V., Guidici G., Alcalay M., Lo Coco F., 
Diverio D., Pogliani E. M., Lanzi E. M., Mandelli F., Masera G., Barbui T., 
and Pelicci P. G. (1992) Molecular monitoring o f the myl / Retinoic acid 
receptor-a fusion gene in acute promyelocytic leukemia by polymerase chain 
reaction. Blood. 80 (2): 492-497
Butler L. H., Slany R., Cui X., Cleaiy M. L., and Mason D. Y. (1997) The HRX 
proto-oncogene product is widely expressed in human tissues and localizes to 
nuclear structures. Blood. 89 (9): 3361-3370
Carlo-Stella C., Mangoni L., Dotti G. P., and Rizzoli V. (1995) Techniques for 
detection of minimal residual disease. Leuk Lymphoma. 18 Suppl 1: 75-80
131
Cimino G., Elia L., Rivolta A., Rapanotti M. C., Rossi V., Alimena G , Annino L., 
Canaani E., Lo Coco F., and Biondi A. (1996) Clinical relevance of residual 
disease monitoring by polymerase chain reaction in patients with ALL-1 / AF- 
4 positive-acute lymphoblastic leukemia. British Journal o f Haematology. 92: 
659-664
Claxton D. F., Liu P., Hsu H. B., Marlton P., Hester J., and Siciliano M. J. (1994) 
Detection o f fusion transcripts generated by the inversion 16 chromosome in 
acute myelogenous leukemia. Blood. 83 (7): 1750-1756
Cortes J. E., Talpaz M., and Kantaijian H. (1996) Chronic myelogenous leukemia: A 
review. The American Journal o f Medicine. 100: 555-570
Cotran R. S., Kumar V., and Robbins S. L. (1989) Robbins Pathologic Basis o f 
Disease. 4^** edition. W. B. Saunders Company
Cuneo A., Bigoni R., Roberti M. G., Bardi A., Balsamo R., Piva N., and Castoldi G. 
(1997) Detection of numerical aberrations in hematologic neoplasias by 
fluorescence in situ hybridization. Haematologica. 82: 85-90
Downing J. R., Head D. R., Curcio-Brint A. M., Hulshof M. G., Motroni T. A., 
Raimondi S. C., Carroll A. J., Drabkin H. A , Willman C., Theil K. S., Civin
C. L, and Erickson P. (1993) An AMLl / ETO fusion transcript is consistently 
detected by RNA-based polymerase chain reaction in acute myelogenous 
leukemia containing the (8;21) (q22;q22) translocation. Blood. 81 (11): 2860- 
2865
132
Eren E., Aytaç U., Görgün A., Kansu E., and Gündüz U. (1996). Kronik myeloid 
lösemide moleküler tam. Çocuk Sağlığı ve Hastalıkları Dergisi. 39; 163-169
Erickson P. F., Robinson M., Owens G., and Drabkin H. A. (1994) The ETO portion 
acute myeloid leukemia t (8;21) fusion transcript encodes a highly 
evolutionary conserved, putative transcription factor. Cancer Res. 54 (71): 
1782-1786
Ezaki K. (1996) Cytokine therapy for hematological malignancies. Int J  Hematol. 65 
(1): 17-29
Fauci A. S., Braunwald E., Isselbacher K. J., Wilson J. D., Martin J. B:, Kasper D. L., 
Hauser S. L., and Longo D. L. (1998) Harrison’s Principles of Internal 
Medicine. 1: 634-724
Frenoy N., Chabli A., Sol O., Goldschmit E., Lemormier M-P., Misset J-L., and 
Debuire B. (1994) Application o f a new protocol for nested PCR to the 
detection o f minimal residual bcr /  abl transcripts. Leukemia. 8 (8): 1411-1414
Giralt S. A., and Champlin R. E. (1994) Leukemia relapse after allogeneic bone 
marrow transplantation; A review. Blood. 84 (11); 3603-3612
Goltsov A. A., Eisensmith R. C., Konecki D. S., Lichter-Konecki U., and Woo S. L. 
(1992) Associations between muations and a VNTR in the human 
phenylalanine hydroxylase gene. Am. J  Hum Genet. 51 (3): 627-636
133
Gosalvez J., Lopez-Feraandez C., Buno I., Polo N., Llamas P., Fernandez M. N., 
Fernandez J. L., and Diez-Martin J. L. (1996) Restriction endonuclease in situ 
digestion (REYSD) and fluorescence in situ hybridization (FISH) as 
complementary methods to analyze chimerism and residual disease after bone 
marrow transplantation. Cancer Genet Cytogenet. 89; 141-145
Guinn B. A., and Padua R. A. (1997) p53; A role in the initiation and progression of 
leukaemia?. Cancer Journal. 8 (4 )
http: // WWW. infobiogen.fi·/ agora/j oumals/ cancer/articles/8-4/guinn-htm
Hermans A., Heisterkamp N., von Lindem M., van Baal S., Meijer D., van der Plas
D., Wiedemann L. M., Groffen J., Bootsma D., and Grosveld G. (1987) 
Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive 
acute lymphoblastic leukemia. Cell. 51: 33-40
http;//www. canceraews.com
http ;//www. ncbi. nlm. gov/htbinpost/Omim/ dispmim? 151410
http://www.ncbi.nlm.gov/htbinpost/Omim/dispmim7189980
Jones P., Qiu J., and Rickwood D. (1994) RNA Isolation and Analysis
Jones R. J. (1998) Transplantation. Current Opinion in Oncology. 10; 93-94
134
Kawasaki E. S., Clark S. S., Coyne M. Y., Smith S. D., Champlin R., Witte O.N., and 
Mc Cormick F. P. (1988) Diagnosis o f chronic myeloid and acute lymphocytic 
leukemias by detection o f leukemia-specific mRNA sequences amplified in 
vitro. Proc. Natl. Acad. Sci, USA. 85: 5698-5702
Kimpton C. P., Gill P., Walton A., Urquhart A., Millican E. S., and Adams M. (1993) 
Automated DNA profiling employing multiplex amplification o f short tandem 
repeat loci. PCR Methods and Applications. 3.13-3.22
Klampfer L., Zhang J., Zelenetz A. O., Uchida H., and Nimer S. D. (1996) The 
AMLl / ETO fusion protein activates transcription o f Bcl-2. Proc. Natl. Acad. 
Sci, USA. 93 (24); 14059-14064
Kurzrock R., and Talpaz M. (1995) Molecular Biology in Cancer Medicine
Lee G. R., Bithell T. C., Foerster J., Athens J. W., Lukens J. N. (1993) Wintrobe’s 
Clinical Hematology. 1, 2
Lichter P., Fischer K., Joos S., Fink T., Badis M.^ Potkul R.K., Ohl S., Solinas-Toldo 
S., Weber R., Stilgenbauer S., Bentz M., Dohner H. (1996) Efficacy o f 
current molecular cytogenetic protocols for the diagnosis of chromosomal 
aberrations in tumor specimens. Cytokines Mol Ther. 2 (3): 163-169
Liu P. P., Hajra A , Wijmenga C., and Collins F. S. (1995) Molecular pathogenesis o f 
the chromosome 16 inversion in the M4Eo subtype o f acute myeloid leukemia. 
Blood. 85 (9): 2289-2302
135
Me Pherson M. J., Quirke P., and Taylor G. R. (1991) PCR A Practical Approach. 
Series editors: Rickwood D., and Hames B. D.
Misawa S., Taniwaki M., and Yokota S. (1995) Detection of minimal residual disease 
by means o f FISH and PCR methods and its clinical evaluation. Rimho 
Ketsueki. 36 (4); 293-298
Miyoshi H., Ohira M., Shimizu K., Mitani K., Hirai H., Imai T., Yokoyama K., Soeda
E., and Ohki M. (1995) Alternative splicing and genomic structure o f the 
AMLl gene involved in acute myeloid leukemia. Nucleic Acids Res. 23 (14): 
2762-2769
Morrissey J., Tkachuk D. C., Milatovich A., Franche U., Link M., and Cleary M. L. 
(1993) A serine / proline-rich protein is fused to HRX in t (4;11) acute 
leukemias. Blood. 81 (5): 1124-1131
Nucifora G., and Rowley J. D. (1994) The AMLl and ETO genes in acute myeloid 
leukemia with a t (8;21). LeukLymphoma. 14 (5-6): 353-362
Okuda T., van Deursen J., Hiebert S. W., Grosveld G., and Downing J. R. (1996) 
AM Ll, the target o f multiple chromosomal translocations in human leukemia, 
is essential for normal fetal liver hematopoiesis. Cell. 84: 321-330
Özbek U., Vural B., Kalayoğlu S., Soysal T., Bilgen H., Yavuz S., Anak S., Sargın 
D., Gedikoğlu G., Ferhanoğlu B., Akoğlu T., Tangün Y., and Özçelik T. 
(1997) Evaluation o f chimerism with DNA polymoiphisms in bone marrow 
transplantation. The Turkish Journal o f Pediatrics. 39: 303-311
136
Pendergast A. M., Muller A. J., Havlik M. H., M am Y., and Witte O. N. (1991) BCR 
sequences essential for transformation by the BCR-ABL oncogene bind to the 
ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. 
Cell. 66 (1); 161-171
Privitera E., Kamps M. P., Hayashi Y., Inaba T., Shapiro L. H., Raimondi S. C., 
Behm F., Hendershot L., Carroll A. J., Baltimore D., and Look A. T. (1992) 
Different molecular consequences o f the 1;19 chromosomal translocation in 
childhood B-cell precursor acute lymphoblastic leukemia. Blood. 79 (7); 1781- 
1788
Raitano A. B., Whang Y. E., and Sawyers C. L. (1997) Signal transduction by wild- 
type and leukemogenic Abl proteins. Biochimica et Biophysica Acta. 1333; 
F201-F216
Rasio D., Schichman S. A.., Negrini M., Canaani E., and Croce C. M. (1996) 
Complete exon stmcture of the ALLI gene. Cancer Res. 56 (8); 1766-1769
Repka T., and Weisdorf D. (1998) Peripheral blood versus bone niarrow for 
hematopoietic cell transplantation. Current Opinion in Oncology. 10: 112-117
Ringden Olle. (1997) Allogeneic bone marrow transplantation for hematological 
malignancies - controversies and recent advances. Acta Oncológica. 36 (6): 
549-564
137
Sacchi S., Russo D., Awisati G., Dastoli G., Lazzarino M., Pelicci P. G., Bonora M. 
R., Visani G., Grassi C., Idcona I., Luzzi L., and Vanzanelli P. (1997) All- 
trans retinoic acid in hematological malignancies. An update. Haematologica. 
82: 106-121
Saglio G. (1995) Minimal residual disease detection in human leukemias: biologic and 
clinical significance. Acta Haematol Pol. 26 (2) Suppl 1: 19-24
Sambrook J., Fritsch E. F., and Maniatis T. (1989) Molecular Cloning: A Laboratory 
Manual. 1, 2, 3
Sawyers C. L., Denny C., T., and Witte O. N. (1991) Leukemia and the disruption o f 
normal hematopoiesis. Cell. 64: 337-350
Schafer A. J., and Hawkins J. R. (1998) DNA variation and the future o f human 
genetics. Nature Biotechnology. 16: 33-39
Segeren C. M., and van’t Veer M. B. (1996) The FAB classification for acute myeloid 
leukaemia- is it outdated? The Netherlands Journal o f Medicine. 49: 126-131
Solomon E., Borrow J., and Goddard A. D. (1991) Chromosome aberrations and 
cancer. Science. 254: 1153-1160
138
Suttorp M., Schmitz N., Dreger P., Schaub J., and Löffler H. (1993) Monitoring o f 
chimerism after allogeneic bone marrow transplantation with unmanipulated 
marrow by use o f DNA polymorphisms. Leukemia. 7 (5): 679-687
Tabbara I. A. (1996) Allogeneic bone marrow transplantation: Acute and late 
coví^ \)X\cг.i\ovıs. Anticancer Research. 16; 1019-1026
Toren A., Rechavi G., and Nagler A. (1996) Minimal residual disease post-bone 
marrow transplantation for hemato-oncological diseases. Stem Cells. 14 (3): 
300-311
Ugozzoli L., Yam P., Petz L. D., Ferrara G. B., Champlin R. E., Forman S. J., Koyal 
D., and Wallace R. B. (1991) Amplification by the polymerase chain reaction 
o f hypervariable regions o f the human genome for evaluation o f chimerism 
after bone marrow transplantation. Blood. 77 (7): 1607-1615
Wada C., Shionoya S., Fujino Y., Tokuhiro H., Akahoshi T., Uchida T., and Ohtani 
H. (1994) Genomic instability o f microsatellite repeats and its association with 
the evolution of chronic myelogenous leukemia. Blood. 83: 3449-3456
Wang J., Wang M., and Liu J. M. (1997) Transformation properties of the ETO gene, 
fusion partner in t (8;21) leukemias. Cancer Research. 57 (14): 2951-2955
Wang Z. G., Delva L.' Gaboli M., Rivi R., Giorgio M., Cordon-Cardo C., Grosveld
F., and Pandolfi P. P. (1998) Role of PML in cell growth and the retinoic acid 
pathway. Science. 279; 1547-1551
139
Widzysska L, and Kuratowska Z. (1995) Clinicl significance and prognostc detection 
o f minimal residual disease in acute leukemias. Acta Haematol Pol. 26 (4); 
413-420
Wilson J. D., Braunwald E., Isselbacher K. J., Petersdorf R. G., Martin J. B., Fauci A. 
S., and Root R. K. (1991) Harrison’s Principles o f Internal Medicine
Yergeau D. A., Hetherington C. J., Wang Q., Zhang P., Sharpe A. H., Binder M., 
Padilla M. M., Tenen D. G., Speck N. A., and Zhang D-E. (1997) Embryonic 
lethality and impairment o f haematopoiesis in mice heterozygous for an 
AMLl-ETO  fusion gene. Nature Genetics. 15: 303-306
140
